

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 882 714 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
03.03.2004 Bulletin 2004/10

(21) Application number: **97940447.2**

(22) Date of filing: **22.09.1997**

(51) Int Cl.7: **C07D 213/69**, C07D 213/70,
C07D 213/79, C07D 213/80,
C07D 401/06, C07D 409/06,
C07D 405/14, C07D 417/14,
C07D 521/00, A61K 31/44,
C07D 405/12

(86) International application number:
PCT/JP1997/003354

(87) International publication number:
WO 1998/013348 (02.04.1998 Gazette 1998/13)

(54) **SUBSTITUTED VINYLPIRIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME**
SUBSTITUIERTE VINYLPIRIDINDERIVATE UND ARZNEIMITTEL, DIE DIESE ENTHALTEN
DERIVES DE VINYLPIRIDINE SUBSTITUES ET MEDICAMENTS LES CONTENANT

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**

(30) Priority: **25.09.1996 JP 25294496**

(43) Date of publication of application:
09.12.1998 Bulletin 1998/50

(73) Proprietor: **SS Pharmaceutical Co., Ltd.**
Tokyo 103 (JP)

(72) Inventors:
• **YAMAZAKI, Kazuo**
Sawara-shi, Chiba 287 (JP)
• **OGAWA, Yoichiro**
Chiba-shi, Chiba 262 (JP)
• **KOHYA, Hidehiko**
Narita-shi, Chiba 286 (JP)
• **MIKAMI, Tadashi**
Sawara-shi, Chiba 287 (JP)
• **KAWAMOTO, Noriyuki**
Narita-shi, Chiba 286 (JP)
• **SHIOIRI, Noriaki**
Narita-shi, Chiba 286 (JP)

• **HASEGAWA, Hiroshi**
Sakura-shi, Chiba 285 (JP)
• **SATO, Susumu**
Narita-shi, Chiba 286 (JP)

(74) Representative:
Wächtershäuser, Günter, Prof. Dr.
Wächtershäuser & Hartz
Patentanwälte
Weinstrasse 8
80333 München (DE)

(56) References cited:
EP-A- 0 157 420 WO-A-94/20455
WO-A-95/20578 WO-A-97/33870

• **CURR. PHARM. DES., Vol. 1, No. 2, LOBARDO**
L.J., "Phosphodiesterase-IV Inhibitors: Novel
Therapeutics, for the Treatment of Inflammatory
Diseases", pages 255-268.
• **CIRC. SHOCK., Vol. 44, No. 3, LEE J.C.,**
PRABHAKAR U., GRISWOLD D.E.,
DUNNINGTON D., YOUNG P.R., BADGER A.,
"Low-Molecular-Weight TNF Biosynthesis
Inhibitors: Strategies and Prospectives", pages
97-103.

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 882 714 B1

Description

TECHNICAL FIELD

[0001] The present invention relates to a substituted vinylpyridine derivative and salts thereof, which are endowed with strong and selective phosphodiesterase (PDE) IV inhibitory action and strong inhibitory action against production of the tumor necrotizing factor (TNF- α), as well as with high safety. The invention also relates to drugs and a pharmaceutical composition containing the derivative or salts and useful for the prevention and treatment of a broad range of inflammatory diseases and autoimmune diseases.

BACKGROUND ART

[0002] PDE is an enzyme which acts as a catalyst in hydrolysis of cyclic adenosine 3',5'-phosphate (cAMP) or cyclic guanosine 3',5'-phosphate (cGMP) into 5'-monophosphate. cAMP and cGMP are produced from ATP and GTP, respectively, following activation of adenylate cyclase or guanylate cyclase in response to a hormone or chemical transmission substance, and work as intracellular second messengers. PDE inhibitory agents block the activity of PDE to increase the amounts of intracellular cAMP and cGMP, to thereby suppress cellular response. At present, PDE is known to have type I to type VIII isozymes. These are found in the central nervous system, circulatory system, respiratory system, digestive system, reproductive system, and blood cell system. The distribution of these isozymes differs according to the tissue. This suggests that a PDE-isozyme-specific inhibitor may increase the amount of cAMP in certain specific tissue.

[0003] In recent years, considerable efforts have been devoted to research and development of highly specific PDE isozyme inhibitors. For example, attempts have been made to develop drugs that exhibit organ specificity attributable to localization of respective isozymes. As a result of such attempts, PDE IV is considered to be a potential agent effective for both asthmatic attack and chronic respiratory tract inflammation, due to the facts that PDE IV is present predominantly in the airway tissue or inflammatory cells, such as eosinocytes and neutrophilic leukocytes, which are intimately related to asthmatic symptoms and that drugs that inhibit the action of PDE IV exhibit bronchodilatation action as well as inhibitory action against activation of inflammatory leukocytes. Thus, active studies have been performed worldwide focusing on development of a selective inhibitor against PDE IV as a new remedy for bronchial asthma.

[0004] PDE IV, which also exists in the central nervous system, is expected to improve memory and mitigate anxiety, based on the consideration that a rolipram, a selective PDE IV inhibitor, specifically localizes in the brain tissue to increase noradrenergic nervous transmission on a synapse or post-synapse level in response to an increased amount of cAMP, which is a second messenger of noradrenalin.

[0005] TNF- α is a cytokine produced by an activated macrophage. Although TNF- α was first discovered to be a factor which induces hemorrhagic necrosis in a tumor site, it is now recognized as a mediator which widely participates in inflammatory reactions and the immune mechanism. Excessive production of TNF- α , however, induces disorders in tissue to cause a variety of pathological conditions. Rapid release of TNF- α induced by intracellular toxins is responsible for the lethality.

[0006] TNF- α promotes production of platelet-activating factor (PAF), a variety of inflammatory arachidonic metabolites, and activated oxygen. Moreover, it induces production of interleukin(IL)-1, IL-6, and IL-8. As is understood from this, excessive production of TNF- α aggravates inflammatory reactions and, in the case of chronic inflammatory diseases such as rheumatism, osteoporosis, and terminal cancers, results in a persistence of complication of diseases, in which the concentrations of these cytokines are maintained consistently so as exacerbate the symptoms. Accordingly, in pathological conditions in which TNF- α is produced excessively, control of its release is strongly sought by clinicians.

[0007] So far, molecular design of a selective PDE IV inhibitor has not yielded satisfactory results, and therefore limitation is imposed on use of the selective PDE IV inhibitor. Theophylline, which is a xanthine-based drug widely used by clinicians as a therapeutic agent for the treatment of bronchial asthma, exhibits bronchodilating action stemming from the adenosine antagonizing action and PDE inhibitory action. However, theophylline sometimes causes adverse side effects in the circulatory system and central nervous system, as it inhibits PDE non-selectively. Thus, the safety range of theophylline is rather narrow. Rolipram and Ro20-1724 selectively inhibit PDE IV at a potency 100 times that at which they inhibit other PDE isozymes. However, the inhibitory power itself is not significant, imposing limitations on applicable diseases.


[0008] TNF- α production inhibitors include antiphlogistic steroids, antihistaminic agents, PAF antagonists, and active-oxygen quencher. However, these are nonspecific inhibitors with either weak power or, when their power is strong, with low tissue specificity, thus limiting their methods of use. Moreover, protease inhibitors have recently been reported to be specific TNF- α production inhibitors. The protease inhibitors are peptide derivatives and have not yet been extensively studied with regard to administration methods, etc.

[0009] Accordingly, the present invention is directed to the provision of therapeutics for a variety of diseases based on the selective PDE IV inhibitory action; the provision of therapeutics for a variety of diseases based on the TNF- α production inhibitory action; and the provision of drugs for the prevention and treatment of a wide variety of inflammatory diseases and autoimmune diseases, which drugs are designed based on concurrent actions of these two actions and are endowed with enhanced effects, higher specificity, and higher safety.

DISCLOSURE OF THE INVENTION

[0010] Under the above circumstances, the present inventors synthesized numerous compounds, and studied their PDE inhibitory action and inhibitory action against production of a variety types of cytokines, and as a result found that the substituted vinylpyridine derivatives represented by formula (1) or salts thereof potently and selectively inhibit PDE IV only, while not acting on other PDE isozymes, and that production of TNF- α is potently inhibited. As a result, the below-described substituted vinylpyridine derivatives have been shown to be effective for the prevention and treatment of the aforementioned wide ranges of inflammatory diseases, autoimmune diseases, and other diseases associated with disturbed metabolism of the cerebrum. The present invention has been completed based on these findings.

[0011] Accordingly, the present invention provides a substituted vinylpyridine derivative represented by the following formula (1):



according to claim 1.

[0012] The present invention also provides a drug containing as the active ingredient a substituted vinylpyridine derivative represented by the above-described formula (1), a salt thereof, a hydrate thereof, or an N-oxide thereof.

[0013] The present invention also provides a pharmaceutical composition containing a substituted vinylpyridine derivative represented by the above-described formula (1), a salt thereof, a hydrate thereof, or an N-oxide thereof; and a pharmacologically acceptable carrier.

[0014] The present invention further provides use, as a drug, of a substituted vinylpyridine derivative represented by the above-described formula (1), a salt thereof, a hydrate thereof, or an N-oxide thereof for the manufacture of a medicament.

[0015] The present specification still further discloses a preventive or therapeutic method for a disease caused by the production of PDE IV or TNF- α , which method comprises the step of administering to a mammal including a human an effective amount of a substituted vinylpyridine derivative represented by the above-described formula (1), a salt thereof, a hydrate thereof, or an N-oxide thereof.

BEST MODE FOR CARRYING OUT THE INVENTION

[0016] In the substituted vinylpyridine derivative of formula (1) of the present invention, examples of alkyl groups represented by R¹ include C1-12 linear, branched, cyclic, cyclic-linear, or cyclic-branched alkyl groups: Of these, linear or branched alkyl groups are preferably C1-8 alkyl groups, and examples include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, n-pentyl, i-pentyl, n-hexyl, n-heptyl, and n-octyl. Cyclic alkyl groups are preferably C3-8 cycloalkyl groups, and examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and norbornyl. Cyclic-linear or cyclic-branched alkyl groups are preferably C4-12 alkyl groups, and examples include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclopropylethyl, cyclobutylethyl, and cyclopentylethyl.

[0017] Examples of alkenyl groups include C2-12 linear, branched, or cyclic alkenyl groups. Of these, C5-8 cyclic alkenyl groups are preferred, and examples include 3-cyclopentenyl, 2-cyclohexenyl, 3-cyclohexenyl, 4-cycloheptenyl, and norbornenyl.

[0018] Hydroxyalkyl groups may be linear, branched, or cyclic, and may be substituted with one or more hydroxy groups. Hydroxyalkyl groups have preferably 2-12 carbon atoms, more preferably 2-8 carbon atoms. Examples of linear or branched hydroxyalkyl groups include 2-hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl, 5-hydroxypentyl, and 6-hydroxyhexyl. Cyclic hydroxyalkyl groups are preferably C4-8 hydroxycycloalkyl groups, and examples include 3-hydroxycyclobutyl, 3-hydroxycyclopentyl, 3-hydroxycyclohexyl, and 4-hydroxycyclohexyl. Dihydroxyalkyl groups are preferred.

ably C3-7 dihydroxyalkyl groups, and examples include 1,3-dihydroxy-2-propyl, 1,5-dihydroxypentyl, and 1,7-dihydroxyheptyl. A hydroxy group of these hydroxyalkyl groups may be substituted with an alkoxy carbonyl group, an acyl group, or a TBS (t-butyldimethylsilyl) group.

[0019] Alkoxyalkyl groups are preferably those whose total carbon number is 2-12, and examples include methoxymethyl, methoxyethyl, and ethoxyethyl.

[0020] Alkoxyalkoxyalkyl groups are preferably those whose total carbon number is 3-12, and examples include methoxyethoxymethyl.

[0021] Alkoxy carbonylalkyl groups are preferably those whose total carbon number is 3-13, and examples include methoxycarbonylmethyl and ethoxycarbonylethyl.

[0022] Examples of aminoalkyl groups which may be substituted include C2-12 linear or branched aminoalkyl or diaminoalkyl groups. Of these, C2-8 linear or branched aminoalkyl groups are preferred, and examples include 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, and 6-aminohexyl. Diaminoalkyl groups are preferably those having 3-7 carbon atoms, and examples include 1,3-diamino-2-propyl, 1,5-diaminopentyl, and 1,7-diaminoheptyl. An amino group of these aminoalkyl groups may be substituted with an alkoxy carbonyl group, an acyl group, etc.

[0023] Saturated heterocyclic groups include a 5-6-membered heterocycle having an oxygen atom, a sulfur atom, or a nitrogen atom as a hetero atom. Examples of these include 2-tetrahydropyranyl, 3-tetrahydropyranyl, 2-tetrahydrofuranyl, and 3-tetrahydrofuranyl.

[0024] Examples of aralkyl groups which may be substituted include benzyl, phenethyl, phenylpropyl, and phenylbutyl; benzyl, phenethyl, and phenylpropyl having one or plurality of methoxy group(s), alkoxy carbonyl group(s), or alkylenedioxy group(s) at o-, m-, and/or p-position. The alkoxy groups preferably have 1-6 carbon atom(s), and examples include methoxy, ethoxy, n-propoxy, and i-propoxy.

[0025] Benzocycloalkyl groups which may be substituted have 9-11 carbon atoms, and examples include 1-indanyl, 2-indanyl, 1,2,3,4-tetrahydro-1-naphthyl and 1,2,3,4-tetrahydro-2-naphthyl. Examples of alkyl groups which may have a (optionally substituted) heterocyclic group include C1-5 linear alkyl groups substituted with an aromatic heterocycle, a saturated heterocycle, or an unsaturated heterocycle. Of these, aromatic heterocycles may be 5- or 6-membered heteroaryl groups having 1-3 nitrogen atom(s), oxygen atom(s), or sulfur atom(s), and examples include 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 2-pyrazyl, 2-thiazolyl, 5-thiazolyl, 4-methyl-5-thiazolyl, 1-imidazolyl, 2-imidazolyl, 3-imidazolyl, 2-oxazolyl, 2-thienyl, 3-thienyl, and 2-furanyl. Saturated or unsaturated heterocycles may be 5-7-member groups having 1-3 nitrogen atom(s), oxygen atom(s), or sulfur atom(s), and examples include 1-pyrrolidyl, 1-piperidyl, 1-azepanyl, 1-morpholino, pyrrolidin-2-on-1-yl, and pyridin-2-on-1-yl.

[0026] Substituents in benzocycloalkyl groups or a heterocyclic group of heterocycle-substituted alkyl groups may be 1-3 group(s) selected from hydroxy, halogeno, C1-6 alkyl, C1-6 alkoxy, C1-6 halogenoalkyl, cyano, and nitro.

[0027] Alkyl groups represented by R² preferably have 1-6 carbon atom(s), and examples include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, and tert-butyl.

[0028] Alkoxy groups of alkoxy carbonyl groups represented by R³ preferably have 1-6 carbon atom(s), and examples include methoxy, ethoxy, n-propoxy, and i-propoxy.

[0029] Examples of monocyclic (optionally substituted) aryl groups represented by R⁵ include a phenyl group which may be substituted with 1-3 group(s) selected from halogeno, C1-6 alkyl, C1-6 alkoxy, C1-6 halogenoalkyl, C1-6 alkoxy carbonyl, carboxyl, cyano, and nitro. Examples of these include phenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-ethylphenyl, 2-i-propylphenyl, 2-t-butylphenyl, 2-methoxyphenyl, 2-trifluoromethylphenyl, 2-cyanophenyl, 2-nitrophenyl, 2-carboxyphenyl, 2-methoxycarbonylphenyl, 2-ethoxycarbonylphenyl, 3-carboxyphenyl, 3-methoxycarbonylphenyl, 3-ethoxycarbonylphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-trifluoromethylphenyl, 4-cyanophenyl, 4-nitrophenyl, 4-carboxyphenyl, 4-methoxycarbonylphenyl, 4-ethoxycarbonylphenyl, 2,6-difluorophenyl, 2,6-dichlorophenyl, 2,6-dibromophenyl, 2,6-dimethylphenyl, 2,6-dimethoxyphenyl, and 2,6-ditrifluoromethylphenyl.

[0030] Examples of condensed-ring (optionally substituted) aryl groups include a naphthyl group which may be substituted with 1-3 group(s) selected from halogeno, C1-6 alkyl, C1-6 alkoxy, C1-6 halogenoalkyl, C1-6 alkoxy carbonyl, carboxyl, cyano, and nitro. Examples of these include 1-naphthyl, 2-naphthyl, 2-chloro-1-naphthyl, and 2-methoxy-1-naphthyl.


[0031] Examples of monocyclic (optionally substituted) heteroaryl groups include a 5-6-membered heteroaryl group (having 1-3 atom(s) of nitrogen, oxygen, or sulfur) which may be substituted with 1-3 group(s) selected from halogeno, C1-6 alkyl, C1-6 alkoxy, C1-6 halogenoalkyl, C1-6 alkoxy carbonyl, carboxyl, cyano, and nitro. Examples of these include 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-carboxy-4-pyridyl, 2-methoxycarbonyl-4-pyridyl, 2-ethoxycarbonyl-4-pyridyl, 3-chloro-4-pyridyl, 3-bromo-4-pyridyl, 3-methoxy-4-pyridyl, 3,5-dichloro-4-pyridyl, 3,5-dibromo-4-pyridyl, 3,5-dimethoxy-4-pyridyl, 3-chloro-5-methoxy-4-pyridyl, 2-pyrimidyl, 2-pyrazyl, 2-thienyl, 3-thienyl, and 2-furanyl.

[0032] Examples of condensed-ring (optionally substituted) heteroaryl groups include a condensed-ring heteroaryl group (containing a nitrogen atom) which may be substituted with 1-3 group(s) selected from halogeno, C1-6 alkyl, C1-6 alkoxy, C1-6 halogenoalkyl, C1-6 alkoxy carbonyl, carboxyl, cyano, and nitro. Examples of these include 2-quinolyl,

4-quinolyl, and 1-isoquinolyl.

[0033] Examples of salts or hydrates of the substituted vinylpyridine derivative of formula (1) of the present invention include hydrochlorides, nitrates, hydrobromides, p-toluenesulfonates, methanesulfonates, fumarates, maleates, malonates, succinates, citrates, tartarates, and hydrates thereof. Examples of N-oxides of the substituted vinylpyridine derivative include pyridine-N-oxides and N-oxides of a monocyclic or condensed-ring heteroaryl group represented by R^5 .


[0034] The substituted vinylpyridine derivative of the present invention is prepared by, for example, the following reaction scheme. Briefly, a known compound (2) is easily derived from kojic acid (which is inexpensive and available in large quantities) through two or three reactions (Step 1); the known compound (2) is processed to yield a key intermediate (3) or (4) of the synthesis of the present invention (Step 2 or 3); and the intermediate is condensed through reaction with commercially available (or separately synthesized) arylaldehydes (R^5 -CHO), arylacetonitriles or arylacetate esters (R^5 -CH₂R⁷) to thereby obtain a compound (1a) of the present invention.



50 wherein one of R^6 and R^7 , which are different from each other, represents a hydrogen atom and the other represents a nitrile group or an alkoxycarbonyl group; Y represents a hydrogen atom or a protective group (preferably benzyl or tetrahydro-2-pyranyl); R^2 and R^5 have the same meanings as described above; R^{1a} is identical to R^1 except when R^1 is a hydrogen atom, with the presence of a protective group being preferred when R^{1a} is a hydroxyalkyl group.

55 **[0035]** In other words, the key intermediate (3) is reacted with R^5 -CHO (Step 4) or the key intermediate (4) is reacted with R^5 -CH₂R⁷ (Step 5) to thereby obtain a compound (1a). These reactions easily proceed in the presence of a base such as sodium alkoxide, sodium amide, alkali hydroxide, alkyllithium, or a tertiary alkylamine. These reactions are preferably conducted in methanol with sodium methoxide or in ethanol with sodium ethoxide in the temperature range from 0°C to room temperature.

[0036] The above-described key intermediate (3) may be easily obtained from the known compound (2) through the following reaction scheme.



wherein R^{1a} and R^2 , and Y have the same meanings as described above and Z represents a leaving group (typically a halogen atom).

[0037] The compound (2) is reacted with halide reagents ($R^{1a}-Z$) to obtain a compound (5). If the compound (5) is having a protective group in Y, then it is de-protected and a compound (5: Y = a hydrogen atom) is derived therefrom (Step 2a). Alternatively, the compound (2: Y = a protective group) is converted to the compound (5: Y = protective group) by Mitsunobu reaction with primary or secondary alcohols and the protective group is removed to thereby obtain the compound (5: Y = a hydrogen atom). Next, the compound (5: Y = a hydrogen atom) is converted to a chloro compound (6) (Step 2b). The compound (6) is further reacted with $M-CN$ to obtain the key intermediate (3: R^6 = a nitrile group), whose nitrile group undergoes an alcoholysis to obtain the other key intermediate (3: R^6 = an alkoxycarbonyl group) (Step 2c).

[0038] Reactions of Step 2a are preferably carried out in a solvent such as an alcohol, tetrahydrofuran, dimethylformamide, or dimethyl sulfoxide in the presence of a base such as potassium carbonate, sodium carbonate, or, in some cases, potassium iodide, or sodium iodide in the temperature range from room temperature to 80°C ; or in a water-alcohol mixed solvent in the presence of sodium hydroxide or potassium hydroxide as a base in the temperature range from 0°C to the reflux temperature. Also, the reaction between the compound (2: Y = a protective group) and $R^{1a}-Z$ proceeds easily, under conditions other than the above-described reaction conditions, i.e., in a solvent such as tetrahydrofuran, 1,2-dimethoxyethane, dioxane, dimethylformamide, or dimethyl sulfoxide in the presence of sodium hydride or potassium hydride as a base in the temperature range from 0°C to room temperature. The reaction between the compound (2: Y = a protective group) and primary or secondary alcohols easily proceeds to yield the compound (5: Y = a protective group) by the typical conditions of Mitsunobu reaction, i.e., in the presence of diethyl azodicarboxylate and triphenylphosphine.

[0039] In Step 2a, preferred examples of substituents of R^{1a} include alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, and (optionally substituted) aralkyl. By Mitsunobu reaction to obtain the compound (5: Y = a protective group), a substituent such as cycloalkyl, cycloalkenyl, heterocycloalkyl, or benzocycloalkyl is preferred.


[0040] When the compound (5: Y = a protective group) is de-protected, there are employed conditions such as hydrogenation by use of a catalyst such as palladium or Raney nickel; reductive removal by use of a compound such as ammonium formate, cyclopentene, or 1,4-cyclohexadiene (for benzyl-substituted compound); or hydrolysis in a water-organic solvent with a mineral acid or an organic acid (for tetrahydro-2-pyranyl compound).

[0041] The reaction between thionyl chloride and the compound (5) proceeds easily without or within a solvent inert to thionyl chloride at room temperature to obtain the chloro compound (6) from the compound (5: Y = a hydrogen atom) (Step 2b).

[0042] Step 2c, in which the key intermediate (3: R^6 = a nitrile group) is obtained from the chloro compound (6), is preferably carried out in a polar and aprotic solvent such as dimethyl sulfoxide or dimethylformamide in the presence of sodium cyanide in the temperature range from room temperature to 100°C . The also reaction is easily performed through the cyano-anion-activation method using a phase transfer catalyst or crown ether.

[0043] The key intermediate (3: R^6 = an alkoxy carbonyl group) is obtained from the key intermediate (3: R^6 = a nitrile group) through conversion of the nitrile group in hydrogen chloride-gas-saturated methanol or a lower alcohol in the temperature range from room temperature to the reflux temperature.

[0044] The above-described key intermediate (4) may be easily obtained from the known compound (2) through the following reaction scheme.



wherein R^2 has the same meaning as described above.


[0045] The formyl compound (4) is obtained through conversion of the compound (5) obtained in the above-described Step 2a by use of an oxidant (Step 3b); or through oxidation of the compound (2) to obtain a compound (7) (Step 3a), followed by reaction with the halide reagent ($R^{1a}-Z$) (Step 3c).


[0046] Step 3a, in which the compound (7) is obtained from the compound (2), is preferably carried out in a solvent such as tetrahydrofuran, 1,4-dioxane, or dimethylformamide with an excessive amount of active manganese dioxide or barium manganate(VI) as an oxidant in the temperature range from room temperature to 100°C.

[0047] Step 3b, in which the formyl compound (4) is obtained from the compound (5), is easily carried out in a solvent such as chloroform, dichloromethane, or acetone with an excessive amount of active manganese dioxide or barium manganate(VI) as an oxidant in the temperature range from room temperature to the reflux temperature; or through oxidation by a dimethyl sulfoxide/sulfur trioxide-pyridine-complex (Parikh-Doering method) or oxidation by a dimethyl sulfoxide/oxalyl chloride (Swern method). Also, the formyl compound (4) may be obtained through oxidation by pyridinium chlorochromate (PCC) or pyridinium dichromate (PDC).

[0048] Step 3c, in which the formyl compound (4) is obtained from the compound (7), is carried out through reaction with $R^{1a}-Z$ in a solvent such as tetrahydrofuran, 1,2-dimethoxyethane, dimethylformamide, or dimethyl sulfoxide with a base such as sodium hydride or potassium hydride in the temperature range from 0°C to room temperature; or in a solvent such as an alcohol, tetrahydrofuran, dimethylformamide, or dimethyl sulfoxide with a base such as potassium carbonate or sodium carbonate, or in some cases, potassium iodide or sodium iodide in the temperature range from 0°C to 80°C.

[0049] The compound (1b') or (1b'') of the present invention is obtained through removal of an oxyalkyl group from the compound (1a) of the present invention having a methoxymethyl or methoxyethoxymethyl group as R^1 and a hydrogen atom as R^7 (1a') or as R^6 (1a'').







wherein R², R⁵, R⁶, and R⁷ have the same meanings as described above.

[0050] De-protection of the compound (1a') or (1a'') of the present invention is carried out by use of trifluoroacetic acid or diluted acetic acid (for R¹ = a methoxymethyl group) or trifluoroacetic acid (for R¹ = a methoxyethoxymethyl group).


[0051] The compound (1c') or (1c'') of the present invention is obtained through hydrolysis of the compound (1a) of the present invention having an alkoxycarbonyl group as R⁶ and a hydrogen atom as R⁷ (1a'''), or a hydrogen atom as R⁶ and an alkoxycarbonyl group as R⁷ (1a''').



wherein R¹, R², and R⁵ have the same meanings as described above.

[0052] The above hydrolysis reaction is carried out under alkaline conditions through a widely employed method in which hydrolysis is allowed to proceed in a lower alcohol, by use of diluted NaOH aqueous solution or diluted KOH aqueous solution in a temperature range from room temperature to reflux temperature.


[0053] Compound (1a) may also be obtained by reacting compound (1b') or (1b'') of the present invention with a halide reagent (R^{1a}-Z) in the presence of a base, or alternatively, by Mitsunobu reaction between compound (1b') or (1b'') and a primary or secondary alcohol (R^{1a}-OH).



[0054] The substituent-introduction reaction by use of a halide reagent (R^{1a}-Z) is carried out in a solvent such as alcohol, tetrahydrofuran, dimethylformamide, or dimethyl sulfoxide, in the presence of a base such as potassium carbonate or sodium carbonate, or in some cases potassium iodide or sodium iodide, in a temperature range from room

temperature to 80°C. Alternatively, this reaction is carried out in a solvent such as tetrahydrofuran, 1,2-dimethoxyethane, dioxane, dimethylformamide, or dimethyl sulfoxide, by use of sodium hydride or potassium hydride as a base, in a temperature range from 0°C to room temperature. The substituent-introduction reaction through use of a primary or secondary alcohol (R^{1a} -OH) proceeds easily by the typical conditions of Mitsunobu reaction; i.e., in the presence of diethyl azodicarboxylate and triphenylphosphine.

[0055] Among the formula (1) compounds of the present invention, those compounds (1d) in which X is a sulfur atom, are derived using the below-described scheme from the compound (2').



wherein R^{1a} , R^2 , and R^5 have the same meanings as described above, and M represents an alkali metal.

[0056] The compound (2') is first transformed to a dichloro compound (8), then to an acetonitrile compound (9) through reaction with $M-CN$, and after being introduced with an $R^{1a}S$ group to a key intermediate (10). The thus-obtained compound (10) is easily derived to compound (1d) of the present invention through a condensation reaction with R^5-CHO .

[0057] The reactions for obtaining the compound (9) from the compound (8) and obtaining the compound (1d) of the present invention from the key intermediate (10) proceed under conditions same as those described above. The reaction for obtaining a dichloro compound (8) from the compound (2') is carried out through reflux with heat in phosphorus oxychloride. Particularly, the reaction for obtaining the key intermediate (10) from the compound (9) is preferably carried out in a solvent such as alcohol, tetrahydrofuran, dimethylformamide, or dimethyl sulfoxide, in the presence of a base such as potassium carbonate or sodium carbonate in a temperature range from room temperature to 80°C.

[0058] When the compound (2) or (2') is replaced by a 6-alkoxy-5-hydroxy-3-pyridinemethanol ($Q^3=N$) or 5-alkoxy-6-hydroxy-2-picoline ($Q^2=N$), a compound of formula (1) in which Q^2 or Q^3 is a nitrogen atom can be prepared.

[0059] In the above reactions, separation of compound (1) of the present invention from reaction mixtures is carried out using a customary method, e.g., extraction with a solvent, recrystallization, or column chromatography.

[0060] The thus-obtained compound of the present invention exhibits selective and strong PDE IV inhibitory action and inhibitory action against the production of $TNF-\alpha$. Therefore, the compound is useful as a PDE IV inhibitor and a

TNF- α -production inhibitor, and also as a drug led by one for the prevention and treatment of diseases involving PDE IV and/or TNF- α . The drug of the present invention is useful as a therapeutic agent for the prevention and treatment of immediate or delayed asthma, allergies such as airway-hypersensitive allergy and other allergies stemming from the inhibition of activation of inflammatory blood cells such as eosinocytes, autoimmune diseases such as atopy and rheumatism, depression associated with disturbed metabolism of the cerebrum, cerebral infarction, senile dementia, and memory disorders associated with Parkinson's disease, as well as for osteoporosis, type I and type II diabetes, inflammations, cancers, infections with HIV, AIDS, and shock caused by intracellular toxins.

[0061] The compounds of the present invention may be processed into drugs having a variety of forms, including tablets, granules, powders, capsules, inhalants, suspensions, injections, suppositories, and external preparations.

When solid preparations are formed, the compound of the present invention is preferably mixed with a vehicle and if necessary with a binder, a disintegrant, an extender, a coating agent, an agent for sugar-coating, etc., and is subsequently formed into tablets, granules, capsules, suppositories, etc. When injections are prepared, the compound of the present invention is dissolved, dispersed, or emulsified in an aqueous carrier for injections in advance, or alternatively the compound is dissolved or dispersed, or suspended upon use of the compound. Injection preparations may be used by way of intravenous administration, arterial administration, intraperitoneal administration, subcutaneous administration, or dripping.

[0062] When the compounds of the present invention are used as preventive or therapeutic drugs for the aforementioned diseases, their doses, which may differ in accordance with the manner of administration and the age, body weight, and conditions of the patient, are preferably 5-100 mg/day in the case of oral administration to an adult.

EXAMPLES

[0063] The present invention will next be described by way of examples.

Preparation Example 1

Synthesis of 4-substituted-5-alkoxy-2-pyridinemethanols (5) (Process 1):

[0064] A 5-alkoxy-4-hydroxy-2-pyridinemethanol (2) (100 mmol) was dissolved in dimethylformamide (100 ml). To the solution were added potassium carbonate (150 mmol) and potassium iodide (3 mmol). While the mixture was stirred on a 65°C oil bath, a halide reagent (bromocyclopentane in the case of preparation of compound (5a)) (130 mmol) was added dropwise over one hour. The mixture was stirred for 6-12 additional hours under the same conditions. After being cooled, the reaction mixture was poured into cold water and extracted with ethyl acetate. The organic layer was sequentially washed with water and saturated brine, dried, and then concentrated under reduced pressure. The residue was purified by recrystallization or silica gel column chromatography, to thereby obtain compounds (5a) through (5g) shown below.

4-Cyclopentyloxy-5-methoxy-2-pyridinemethanol (5a)

¹H-NMR(CDC₃) δ : 1.40-2.20(8H, m), 3.90(3H, s), 4.68(2H, s), 4.70-5.00(1H, m), 5.35(1H, s), 6.82(1H, s), 8.04(1H, s).

4-Cyclopentyloxy-5-methoxy-2-pyridinemethanol (5b)

¹H-NMR(CDC₃) δ : 1.42(3H, t, J=7.0Hz), 1.50-2.10(8H, m), 4.09(2H, q, J=7.0Hz), 4.65(2H, s), 4.70-4.90(1H, m), 6.73(1H, s), 8.05(1H, s).

5-Methoxy-4-phenethyloxy-2-pyridinemethanol (5c)

¹H-NMR(CDC₃) δ : 3.18(2H, t, J=7.0Hz), 3.91(3H, s), 4.26(2H, t, J=7.0Hz), 4.63(2H, s), 6.75(1H, s), 7.29(5H, s), 8.05(1H, s).

5-Methoxy-4-(3-phenylpropyloxy)-2-pyridinemethanol (5d)

¹H-NMR(CDC₃) δ : 2.00-2.40 (2H, m), 2.83 (2H, t, J=8.0Hz), 3.75(1H, br), 3.92(3H, s), 4.05(2H, t, J=8.0Hz), 4.63(2H, s), 6.70(1H, s), 7.24(5H, s), 8.04(1H, s).

4-Butyloxy-5-methoxy-2-pyridinemethanol (5e)

¹H-NMR(CDCℓ₃) δ : 0.98(3H, t, J=7.0Hz), 1.30-2.00(4H, m), 3.91(3H, s), 4.07(2H, t, J=7.0Hz), 4.66(2H, s), 6.79(1H, s), 8.03(1H, s).

4-(1-Ethylpropyloxy)-5-methoxy-2-pyridinemethanol (5f)

¹H-NMR(CDCℓ₃) δ : 0.96(6H, t, J=7.0Hz), 1.58-2.00(4H, m), 3.90(3H, s), 4.10-4.40(1H, m), 4.65(2H, s), 6.75(1H, s), 8.04(1H, s).

5-Methoxy-4-methoxymethyloxy-2-pyridinemethanol (5g)

¹H-NMR(CDCℓ₃) δ : 3.51(3H, s), 3.95(3H, s), 4.66(2H, s), 5.31(2H, s), 7.04(1H, s), 8.11(1H, s).

Preparation Example 2

Synthesis of 4-substituted-5-alkoxy-2-benzyloxymethylpyridines (5'):

[0065] A 5-alkoxy-2-benzyloxymethyl-4-hydroxypyridine (2) (10 mmol), a secondary alcohol (2-indanol in the case of preparation of compound (5h')) (12.5 mmol), and triphenylphosphine (15 mmol) were dissolved in tetrahydrofuran (300 ml). Diethyl azodicarboxylate (15 mmol) was added dropwise to the solution under stirring at room temperature, and the mixture was stirred for one hour. After addition of water, the reaction mixture was extracted with in chloroform. The organic layer was sequentially washed with water and saturated brine, dried, and then concentrated under reduced pressure. An ether (100 ml) was added to the residue and insoluble substances were removed by filtration. After concentration of the filtrate, the residue was purified by recrystallization or silica gel column chromatography, to thereby obtain compounds (5h') through (5j') shown below.

2-Benzyloxymethyl-4-(2-indanyloxy)-5-methoxypyridine (5h')

¹H-NMR(CDCℓ₃) δ : 3.00-3.60(4H, m), 3.83(3H, s), 4.64(4H, s), 5.10-5.40(1H, m), 7.06(1H, s), 7.10-7.50(9H, m), 8.06(1H, s).

2-Benzyloxymethyl-5-methoxy-4-(exo-2-norbornyloxy)pyridine (5i')

¹H-NMR(CDCℓ₃) δ : 1.00-2.65(10H, m), 3.90(3H, s), 4.10-4.40(1H, m), 4.60(4H, s), 6.95(1H, s), 7.36(5H, s), 8.04(1H, s).

2-Benzyloxymethyl-5-methoxy-4-(tetrahydro-3-furanyloxy)pyridine (5j')

¹H-NMR(CDCℓ₃) δ : 2.05-2.40(2H, m), 3.80-4.10(4H, m), 3.91(3H, s), 4.60(2H, s), 4.62(2H, s), 4.90-5.10(1H, m), 6.92(1H, s), 7.36(5H, s), 8.08(1H, s).

Preparation Example 3

Synthesis of 4-substituted-5-alkoxy-2-pyridinemethanols (5) (Process 2):

[0066] A 4-substituted-5-alkoxy-2-benzyloxymethylpyridine (5') (10 mmol) was dissolved in acetic acid (50 ml). Pd-black (2 g) was added to the solution, which was hydrogenated at room temperature for 2-6 hours. After removal of the catalyst, the filtrate was concentrated under reduced pressure. The residue was fractionated by a chloroform-aqueous saturated sodium hydrogencarbonate solution. The organic layer was dried and concentrated under reduced pressure. The obtained crystalline residue was optionally recrystallized, to thereby obtain compounds (5h) through (5j) shown below.

4-(2-Indanyloxy)-5-methoxy-2-pyridinemethanol (5h)

¹H-NMR(CDCℓ₃) δ : 3.00-3.65(4H, m), 3.84(3H, s), 4.69(2H, s), 5.10-5.40(1H, m), 6.85(1H, s), 7.10-7.40(4H, m), 8.04(1H, s).

5-Methoxy-4-(exo-2-norbornyloxy)-2-pyridinemethanol (5i)

¹H-NMR(CDCℓ₃) δ : 1.00-2.00(8H, m), 2.30-2.60(2H, m), 3.90(3H, s), 4.10-4.40(1H, m), 4.65(2H, s), 6.69(1H, s), 8.03(1H, s).

5-Methoxy-4-(tetrahydro-3-furanyloxy)-2-pyridinemethanol (5j)

¹H-NMR(CDCℓ₃) δ : 2.10-2.40(2H, m), 3.80-4.20(4H, m), 3.91(3H, s), 4.66(2H, s), 4.90-5.10(1H, m), 6.71(1H, s), 8.07(1H, s).

5

Preparation Example 4

Synthesis of 4-substituted-5-alkoxy-2-chloromethylpyridines (6):

10 **[0067]** A 4-substituted-5-alkoxy-2-pyridinemethanol (5) (0.2 mol) was dissolved in dichloromethane (200 ml). Thionyl chloride (0.3 mol) was added dropwise to the solution under stirring at 5°C. The mixture was allowed to react for 30 minutes under the same conditions. The resultant solution was concentrated under reduced pressure and the residue was fractionated by a chloroform-aqueous saturated sodium hydrogencarbonate solution. The organic layer was dried and concentrated under reduced pressure. Obtained crystalline or oily compounds (6a) through (6j) were used for the subsequent reaction without additional purification.

15

2-Chloromethyl-4-cyclopentyloxy-5-methoxypyridine (6a)

¹H-NMR(CDCℓ₃) δ : 1.40-2.10(8H, m), 3.90(3H, s), 4.60(2H, s), 4.75-4.97(1H, m), 6.96(1H, s), 8.07(1H, s),

20

2-Chloromethyl-4-cyclopentyloxy-5-ethoxypyridine (6b)

¹H-NMR(CDCℓ₃) δ : 1.40(3H, t, J=7.0Hz), 1.60-2.10(8H, m), 4.11(2H, q, J=7.0Hz), 4.59(2H, s), 4.70-4.90(1H, m), 6.95(1H, s), 8.05(1H, s).

25

2-Chloromethyl-5-methoxy-4-phenethyloxy pyridine (6c)

¹H-NMR(CDCℓ₃) δ : 3.18(2H, t, J=7.0Hz), 3.92(3H, s), 4.27(2H, t, J=7.0Hz), 4.57(2H, s), 6.94(1H, s), 7.30(5H, s), 8.06(1H, s).

30

2-Chloromethyl-5-methoxy-4-(3-phenylpropyloxy)pyridine (6d)

¹H-NMR(CDCℓ₃) δ : 2.00-2.40(2H, m), 2.83(2H, t, J=8.0Hz), 3.93(3H, s), 4.07(2H, t, J=8.0Hz), 4.57(2H, s), 6.88(1H, s), 7.24(5H, s), 8.06(1H, s).

35

4-Butyloxy-2-chloromethyl-5-methoxypyridine (6e)

¹H-NMR(CDCℓ₃) δ : 0.99(3H, t, J=7.0Hz), 1.30-2.00(4H, m), 3.93(3H, s), 4.09(2H, t, J=7.0Hz), 4.60(2H, s), 6.97(1H, s), 8.06(1H, s).

40

2-Chloromethyl-4-(1-ethylpropyloxy)-5-methoxypyridine (6f)

¹H-NMR(CDCℓ₃) δ : 0.98(6H, t, J=7.0Hz), 1.58-2.00(4H, m), 3.92(3H, s), 4.10-4.40(1H, m), 4.60(2H, s), 6.94(1H, s), 8.07(1H, s).

45

2-Chloromethyl-5-methoxy-4-methoxymethyloxy pyridine (6g)

¹H-NMR(CDCℓ₃) δ : 3.52(3H, s), 3.96(3H, s), 4.59(2H, s), 5.32(2H, s), 7.23(1H, s), 8.13(1H, s).

50

2-Chloromethyl-4-(2-indanyloxy)-5-methoxypyridine (6h)

¹H-NMR(CDCℓ₃) δ : 3.20(2H, dd, J=4.0, 17.0Hz), 3.50(2H, dd, J=6.0, 17.0Hz), 3.87(3H, s), 4.63(2H, s), 5.15-5.40(1H, m), 7.04(1H, s), 7.23(4H, s), 8.06(1H, s).

55

2-Chloromethyl-5-methoxy-4-(exo-2-norbornyloxy)pyridine (6i)

¹H-NMR(CDCℓ₃) δ : 1.00-2.10(8H, m), 2.25-2.60(2H, m), 3.91(3H, s), 4.15-4.40(1H, m), 4.60(2H, s), 6.90(1H, s), 8.04(1H, s).

2-Chloromethyl-5-methoxy-4-(tetrahydro-3-furanyloxy)pyridine (6j)

¹H-NMR(CDCℓ₃) δ : 2.10-2.40(2H, m), 3.80-4.20(4H, m), 3.92(3H, s), 4.61(2H, s), 4.90-5.10(1H, m), 6.90(1H, s), 8.08(1H, s).

5

Preparation Example 5

Synthesis of 4-substituted-5-alkoxy-2-pyridineacetonitriles (3):

10 **[0068]** A 4-substituted-5-alkoxy-2-chloromethylpyridine (6) (0.20 mol) was dissolved in dimethyl sulfoxide (200 ml). Sodium cyanide (0.24 mol) was added to the solution and the mixture was allowed to react at room temperature for 12 hours or at 100°C for one hour, depending on the reaction rate of the substrate. The reaction mixture was poured into water (500 ml), extracted with ethyl acetate, sequentially washed with water and saturated brine, dried, and then concentrated under reduced pressure. The residue was purified by recrystallization or silica gel column chromatography, to thereby obtain compounds (3a) through (3j) shown below.

15

4-Cyclopentyloxy-5-methoxy-2-pyridineacetonitrile (3a)

¹H-NMR(CDCℓ₃) δ : 1.46-2.20(8H, m), 3.84(2H, s), 3.90(3H, s), 4.72-5.00(1H, m), 6.90(1H, s), 8.06(1H, s).

20

4-Cyclopentyloxy-5-ethoxy-2-pyridineacetonitrile (3b)

¹H-NMR(CDCℓ₃) δ : 1.42(3H, t, J=7.0Hz), 1.60-2.20(8H, m), 3.84(2H, s), 4.11(2H, q, J=7.0Hz), 4.75-5.00(1H, m), 6.88(1H, s), 8.04(1H, s).

25

5-Methoxy-4-phenethyloxy-2-pyridineacetonitrile (3c)

¹H-NMR(CDCℓ₃) δ : 3.18(2H, t, J=7.0Hz), 3.82(2H, s), 3.92(3H, s), 4.27(2H, t, J=7.0Hz), 6.86(1H, s), 7.30(5H, s), 8.05(1H, s).

30

5-Methoxy-4-(3-phenylpropyloxy)-2-pyridineacetonitrile (3d)

¹H-NMR(CDCℓ₃) δ : 2.00-2.40(2H, m), 2.84(2H, t, J=8.0Hz), 3.82(2H, s), 3.94(3H, s), 4.08(2H, t, J=8.0Hz), 6.81(1H, s), 7.25(5H, s), 8.06(1H, s).

35

4-Butyloxy-5-methoxy-2-pyridineacetonitrile (3e)

¹H-NMR(CDCℓ₃) δ : 0.99(3H, t, J=7.0Hz), 1.35-2.10(4H, m), 3.86(2H, s), 3.93(3H, s), 4.09(2H, t, J=7.0Hz), 6.90(1H, s), 8.05(1H, s).

40

4-(1-Ethylpropyloxy)-5-methoxy-2-pyridineacetonitrile (3f)

¹H-NMR(CDCℓ₃) δ : 0.98(6H, t, J=7.0Hz), 1.60-2.00(4H, m), 3.85(2H, s), 3.92(3H, s), 4.10-4.40(1H, m), 6.88(1H, s), 8.06(1H, s).

45

5-Methoxy-4-methoxymethyloxy-2-pyridineacetonitrile (3g)

¹H-NMR(CDCℓ₃) δ : 3.52(3H, s), 3.84(2H, s), 3.96(3H, s), 5.32(2H, s), 7.14(1H, s), 8.13(1H, s).

4-(2-Indanyloxy)-5-methoxy-2-pyridineacetonitrile (3h)

50

¹H-NMR(CDCℓ₃) δ : 3.22(2H, dd, J=4.0, 17.0Hz), 3.51(2H, dd, J=6.0, 17.0Hz), 3.86(3H, s), 3.88(2H, s), 5.10-5.40(1H, m), 6.97(1H, s), 7.23(4H, s), 8.05(1H, s).

5-Methoxy-4-(exo-2-norbornyloxy)-2-pyridineacetonitrile (3i)

55

¹H-NMR(CDCℓ₃) δ : 1.10-2.00(8H, m), 2.30-2.70(2H, m), 3.85(2H, s), 3.90(3H, s), 4.15-4.40(1H, m), 6.84(1H, s), 8.03(1H, s).

5-Methoxy-4-(tetrahydro-3-furanyloxy)-2-pyridineacetonitrile (3j)

¹H-NMR(CDCl₃) δ : 2.10-2.50(2H, m), 3.80-4.20(4H, m), 3.86(2H, s), 3.92(3H, s), 4.90-5.20(1H, m), 7.28(1H, s), 8.08(1H, s).

Preparation Example 6

Synthesis of methyl 4-cyclopentyloxy-5-methoxy-2-pyridineacetate (3k):

[0069] A HCl-saturated methanol solution (30 ml) was added to 4-cyclopentyloxy-5-methoxy-2-pyridineacetonitrile (3a) (2.32 g, 10 mmol) and the solution was refluxed for 30 minutes. The reaction mixture was evaporated to dryness. The residue was dissolved in chloroform and the solution was sequentially washed with aqueous saturated sodium hydrogencarbonate solution and saturated brine, then dried, and then concentrated under reduced pressure, to thereby obtain the title compound (2.36 g, yield 89%).

¹H-NMR(CDCl₃) δ : 1.60-2.10(8H, m), 3.72(3H, s), 3.76(2H, s), 3.89(3H, s), 4.70-4.90(1H, m), 6.81(1H, s), 8.04(1H, s).

Preparation Example 7

Synthesis of 3,5-dichloro-4-pyridinecarbaldehyde :

[0070] Under an argon atmosphere, to a solution of diisopropylamine (33.6 ml, 0.24 mol) in tetrahydrofuran (400 ml) at -65°C was added a 1.6 M solution of n-butyl lithium in hexanes (156 ml). After 20 minutes later, a solution of 3,5-dichloropyridine (29.6 g, 0.20 mol) in tetrahydrofuran (150 ml) was added dropwise, and the mixture was stirred for 30 minutes. Subsequently, the mixture was treated with dimethylformamide (23.2 ml, 0.30 mol) in tetrahydrofuran (50 ml), and then stirred for one hour under the same conditions. The reaction mixture was poured into a 5% aqueous ammonium chloride solution (1,000 ml) and extracted with ethyl acetate. The organic layer was sequentially washed with water and saturated brine, dried, and then concentrated under reduced pressure. The residue was chromatographed on silica gel, to thereby obtain the title compound (27.2 g, yield 77%).

¹H-NMR(CDCl₃) δ : 8.63(2H, s), 10.44(1H, s).

Preparation Example 8

Synthesis of 3,5-dimethoxy-4-pyridinecarbaldehyde:

[0071] In a similar manner to that in Preparation Example 7, the title compound was prepared.

¹H-NMR(CDCl₃) δ : 4.02(6H, s), 8.17(2H, s), 10.50(1H, s).

Preparation Example 9

Synthesis of 5-alkoxy-4-chloro-2-chloromethylpyridines (8) :

[0072] Phosphorus oxychloride (10 ml) was added to a 5-alkoxy-4-hydroxy-2-pyridinemethanol (10 mmol) and the solution was refluxed for three hours. The reaction mixture was concentrated under reduced pressure and the residue was fractionated with a chloroform-aqueous saturated sodium hydrogencarbonate solution. The obtained organic layer was dried and then concentrated under reduced pressure. An obtained crystalline compound (8a) described below was used for the subsequent reaction without additional purification.

4-Chloro-2-chloromethyl-5-methoxypyridine (8a)

¹H-NMR(CDCl₃) δ : 4.00(3H, s), 4.60(2H, s), 7.50(1H, s), 8.25(1H, s).

Preparation Example 10

Synthesis of 5-alkoxy-4-chloro-2-pyridineacetonitrile (9):

- 5 **[0073]** The procedure of Preparation Example 5 was repeated through use of 5-alkoxy-4-chloro-2-chloromethylpyridine (8) and sodium cyanide, to thereby obtain a compound (9a) shown below.
4-chloro-5-methoxy-2-pyridineacetonitrile (9a)

¹H-NMR(CDCℓ₃) δ : 3.87(2H, s), 4.01(3H, s), 7.44(1H, s), 8.23(1H, s),

10

Preparation Example 11

Synthesis of 4-substituted-thio-5-alkoxy-2-pyridineacetonitriles (10) :

- 15 **[0074]** A 5-alkoxy-4-chloro-2-pyridineacetonitrile (9) (4.5 mmol) was dissolved in dimethylformamide (9 ml). To the solution were added potassium carbonate (5.4 mmol) and R^{1a}SH (cyclopentanethiol in the case of preparation of compound (10a)) (5.2 mmol) and the mixture was stirred on a 60°C oil bath for 3-12 hours. After being cooled, the reaction mixture was poured into cold water and extracted with ethyl acetate. The organic layer was sequentially washed with water and saturated brine, dried, and then concentrated under reduced pressure. The residue was purified by
20 recrystallization or silica gel column chromatography, to thereby obtain a compound (10a) shown below.
4-Cyclopentylthio-5-methoxy-2-pyridineacetonitrile (10a)

¹H-NMR(CDCℓ₃) δ : 1.55-2.40(8H, m), 3.55-3.30(1H, m), 3.87(2H, s), 3.97(3H, s), 7.20(1H, s), 7.99(1H, s).

25 Preparation Example 12

Synthesis of 3-fluoro-4-pyridinecarbaldehyde ;

- [0075]** The procedure of Preparation Example 7 was repeated to thereby obtain the title compound.

30

¹H-NMR(CDCℓ₃) δ : 7.71(1H, t, J=5.0Hz), 8.65(1H, d, J=5.0Hz), 8.73(1H, d, J=1.0Hz), 10.45(1H, s).

Preparation Example 13

- 35 Synthesis of 3,5-dichloro-4-pyridinecarbaldehyde N-oxide:

- [0076]** To a benzene solution (100 ml) of 3,5-dichloro-4-pyridinecarbaldehyde (Preparation Example 7) (5.00 g, 28.4 mmol) were added ethylene glycol (10 ml) and p-toluenesulfonic acid hydrate (0.19 g, 1.0 mmol). The mixture, placed in a reaction vessel equipped with a Dean-Stark water separator, was refluxed for eight hours. After being cooled, the reaction mixture was washed with water, dried, and then concentrated under reduced pressure, to thereby obtain the corresponding acetal compound (6.19 g, yield 99%).

40

¹H-NMR(CDCℓ₃) δ : 3.95-4.22(4H, m), 6.38(1H, s), 8.49(2H, s).

- 45 **[0077]** The above-described acetal compound (5.50 g, 25 mmol) was dissolved in dichloromethane (50 ml). To the solution was added 85% m-chloroperbenzoic acid (6.10 g, 30 mmol), and the mixture was stirred at room temperature for 15 hours. The reaction mixture was washed with an aqueous saturated sodium hydrogencarbonate solution, dried, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography, to thereby obtain the corresponding N-oxide compound (5.24 g, yield 89%).

50

¹H-NMR(CDCℓ₃) δ : 3.95-4.22(4H, m), 6.28(1H, s), 8.15(2H, s).

- [0078]** The above-described N-oxide compound (4.72 g, 20 mmol) was dissolved in acetone (40 ml)-H₂O (10 ml) solution. To the solution was added p-toluenesulfonic acid hydrate (3.80 g, 20 mmol). The mixture was refluxed for two hours. The reaction mixture was evaporated to dryness. An aqueous saturated sodium hydrogencarbonate solution was added to the residue, which was then extracted with chloroform. The organic layer was washed, dried, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography, to thereby obtain 3,5-dichloro-4-pyridinecarbaldehyde N-oxide (3.78 g, yield 98%).

55

¹H-NMR(CDCℓ₃) δ : 8.19(2H, s), 10.35(1H, s).

Preparation Example 14

5 Synthesis of 4-(2-indanyloxy)-5-methoxy-2-pyridinecarbaldehyde:

[0079] To a dimethyl sulfoxide solution (20 ml) of 4-(2-indanyloxy)-5-methoxy-2-pyridinemethanol (5h) (2.71 g, 10 mmol) and triethylamine (3.03 g, 30 mmol) was added sulfur trioxide-pyridine complex (4.77 g, 30 mmol), and the mixture was stirred at room temperature for 7 hours. The reaction mixture was poured into cold water to cause precipitation of crude crystals. The crude crystals were collected by filtration, dried, and purified by silica gel column chromatography, to thereby obtain the title compound (1.95 g, yield 72%).

¹H-NMR(CDCℓ₃) δ : 3.10-3.70(4H, m), 3.96(3H, s), 5.20-5.42(1H, m), 7.23(4H, s), 7.55(1H, s), 8.27(1H, s), 9.95(1H, s).

15 Preparation Example 15

Synthesis of N-hydroxyethyl-2-pyridone:

[0080] 2-Pyridone (4.76 g, 50 mmol) and ethyl bromoacetate (10.02 g, 60 mmol) were dissolved in acetone (100 ml). Potassium carbonate (8.28 g, 60 mmol) was added to the solution and the mixture was refluxed for two hours with stirring. After being cooled, insoluble substances were removed by filtration and the filtrate was evaporated to dryness. The residue was purified by silica gel column chromatography, to thereby obtain N-ethoxycarbonylmethyl-2-pyridone (7.60 g, yield 84%).

¹H-NMR(CDCℓ₃) δ : 1.29(3H, t, J=7.0Hz), 4.24(2H, q, J=7.0Hz), 4.64(2H, s), 6.10-6.30(1H, m), 6.60(1H, d, J=9.0Hz), 7.15-7.42(2H, m).

[0081] In 100 ml of dioxane, was dissolved N-ethoxycarbonylmethyl-2-pyridone (3.62 g, 20 mmol). To the solution was added 90% LiBH₄ (0.96 g, 40 mmol) and the mixture was refluxed for 20 minutes. Subsequently, ethyl acetate (20 ml) was added to the mixture and the refluxing was carried out for five minutes. The reaction mixture was evaporated to dryness and water was added to the residue. The aqueous solution was extracted with chloroform (three times), dried, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography, to thereby obtain the title compound (1.15 g, yield 41%).

¹H-NMR(CDCℓ₃) δ : 3.80-4.30(5H, m), 6.10-6.62(2H, m), 7.20-7.50(2H, m).

Preparation Example 16

40 Synthesis of 5-cyclopentyloxy-6-methoxy-3-pyridine acetonitrile:

[0082] The procedure of Preparation Example 1 was repeated through use of 5-hydroxy-6-methoxy-3-pyridinemethanol and bromocyclopentane, to thereby obtain 5-cyclopentyloxy-6-methoxy-3-pyridinemethanol.

¹H-NMR(CDCℓ₃) δ : 1.50-2.20(8H, m), 3.98(3H, s), 4.60(2H, s), 4.73(1H, m), 7.10(1H, d, J=2.0Hz), 7.63(1H, d, J=2.0Hz).

[0083] The procedure of Preparation Example 4 was repeated through use of 5-cyclopentyloxy-6-methoxy-3-pyridinemethanol and thionyl chloride, to thereby obtain 3-chloromethyl-5-cyclopentyloxy-6-methoxypyridine.

¹H-NMR(CDCℓ₃) δ : 1.50-2.10(8H, m), 3.93(3H, s), 4.54(2H, s), 4.70(1H, m), 7.06(1H, d, J=2.0Hz), 7.67(1H, d, J=2.0Hz).

[0084] The procedure of Preparation Example 5 was repeated through use of 3-chloromethyl-5-cyclopentyloxy-6-methoxypyridine and sodium cyanide, to thereby obtain 5-cyclopentyloxy-6-methoxy-3-pyridineacetonitrile.

¹H-NMR(CDCℓ₃) δ : 1.50-2.20(8H, m), 3.67(2H, s), 3.98(3H, s), 4.75(1H, m), 6.99(1H, d, J=2.0Hz), 7.61(1H, d, J=2.0Hz).

Preparation Example 17

Synthesis of 6-cyclopentyloxy-5-methoxy-2-pyridineacetonitrile:

- 5 **[0085]** The procedure of Preparation Example 1 was repeated through use of 6-hydroxy-5-methoxy-2-picoline and bromocyclopentane, to thereby obtain 6-cyclopentyloxy-5-methoxy-2-picoline.

¹H-NMR(CDCℓ₃) δ : 1.58-2.03(8H, m), 2.36(3H, s), 3.80(3H, s), 5.44(1H, m), 6.59(1H, d, J=8.0Hz), 6.92(1H, d, J=8.0Hz).

10

6-Cyclopentyloxy-5-methoxy-2-picoline (0.83 g, 4.0 mmol) and N-bromosuccinimide (0.80 g, 4.4 mmol) were dissolved in carbon tetrachloride (10 ml). The solution in which benzoyl peroxide was added in a catalytic amount was refluxed for two hours. After being cooled, water was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with water, dried, and then concentrated under reduced pressure, to thereby obtain a residue which was used for the subsequent reaction.

15

[0086] The procedure of Preparation Example 5 was repeated through use of the above-described residue and sodium cyanide, to thereby obtain 6-cyclopentyloxy-5-methoxy-2-pyridineacetonitrile (0.72 g, yield 77%).

¹H-NMR(CDCℓ₃) δ : 1.50-2.40(8H, m), 3.73(2H, s), 3.84(3H, s), 5.40(1H, m), 6.80(1H, d, J=8.0Hz), 7.00(1H, d, J=8.0Hz).

20

Preparation Example 18

Synthesis of 5-methoxy-4-[2-(4-methyl-5-thiazolyl)ethyloxy]-2-pyridineacetonitrile:

25

[0087] The procedure of Preparation Example 1 was repeated through use of 4-hydroxy-5-methoxy-2-pyridinemethanol and 5-(2-chloroethyl)-4-methylthiazole, to thereby obtain 5-methoxy-4-[2-(4-methyl-5-thiazolyl)ethyloxy]-2-pyridinemethanol.

¹H-NMR(CDCℓ₃) δ : 2.46(3H, s), 3.33(2H, t, J=6.5Hz), 3.92(3H, s), 4.22(2H, t, J=6.5Hz), 4.65(2H, s), 6.75(1H, s), 8.07(1H, s), 8.61(1H, s).

30

[0088] The procedure of Preparation Example 4 was repeated through use of 5-methoxy-4-[2-(4-methyl-5-thiazolyl)ethyloxy]-2-pyridinemethanol and thionyl chloride, to thereby obtain 2-chloromethyl-5-methoxy-4-[2-(4-methyl-5-thiazolyl)ethyloxy]pyridine.

35

¹H-NMR(CDCℓ₃) δ : 2.47(3H, s), 3.34(2H, t, J=6.5Hz), 3.94(3H, s), 4.25(2H, t, J=6.5Hz), 4.59(2H, s), 6.94(1H, s), 8.08(1H, s), 8.61(1H, s).

40

[0089] The procedure of Preparation Example 5 was repeated through use of 2-chloromethyl-5-methoxy-4-[2-(4-methyl-5-thiazolyl)ethyloxy]pyridine and sodium cyanide, to thereby obtain 5-methoxy-4-[2-(4-methyl-5-thiazolyl)ethyloxy]-2-pyridineacetonitrile.

¹H-NMR(CDCℓ₃) δ : 2.47(3H, s), 3.35(2H, t, J=6.5Hz), 3.85(2H, s), 3.93(3H, s), 4.24(2H, t, J=6.5Hz), 6.87(1H, s), 8.07(1H, s), 8.62(1H, s).

45

Example 1

Synthesis of (Z)-2-(4-cyclopentyloxy-5-methoxy-2-pyridyl)-3-(3,5-dichloro-4-pyridyl)propenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O):

50

[0090] 4-Cyclopentyloxy-5-methoxy-2-pyridineacetonitrile (3a) (16.24 g, 70 mmol) and 3,5-dichloro-4-pyridinecarbaldehyde (Preparation Example 7) (12.94 g, 73.5 mmol) were dissolved in methanol (180 ml). While the solution was stirred at 5°C, a CH₃ONa-CH₃OH solution (1 M, 77 ml) was added dropwise. The mixture was stirred for 30 additional minutes under the same conditions. Precipitated crystals were collected by filtration and recrystallized from ethanol, to thereby obtain the title compound (24.83 g, yield 91%).

55

Melting point: 126-126.5°C

¹H-NMR(CDCℓ₃) δ : 1.60-2.15(8H, m), 3.98(3H, s), 4.92-4.98(1H, m), 7.26(1H, s), 8.19(1H, s), 8.20(1H, s), 8.61(2H, s).

Example 2

[0091] The procedure of Example 1 was repeated through use of 4-cyclopentylloxy-5-methoxy-2-pyridineacetonitrile (3a) and 2,6-dichlorobenzaldehyde, to thereby obtain the compound shown below.

[0092] (Z)-2-(4-Cyclopentylloxy-5-methoxy-2-pyridyl)-3-(2,6-dichlorophenyl)propenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 2, 6-dichlorophenyl, and X = O)

Melting point: 129-130°C

¹H-NMR(CDCℓ₃) δ : 1.60-2.20(8H, m), 3.97(3H, s), 4.92-4.98(1H, m), 7.25(1H, s), 7.26-7.31(1H, m), 7.42(2H, d, J=7.0Hz), 8.20(1H, s), 8.23(1H, s).

Example 3

[0093] The procedure of Example 1 was repeated through use of 4-cyclopentylloxy-5-methoxy-2-pyridineacetonitrile (3a) and 3-pyridinecarbaldehyde, to thereby obtain the compound shown below.

[0094] (Z)-2-(4-Cyclopentylloxy-5-methoxy-2-pyridyl)-3-(3-pyridyl)propenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3-pyridyl, and X = O)

Melting point: 122.5-123.5°C

¹H-NMR(CDCℓ₃) δ : 1.50-2.20(8H, m), 3.98(3H, s), 4.84-5.06(1H, m), 7.30(1H, s), 7.48(1H, dd, J=5.0.8.0Hz), 8.20(1H, s), 8.38(1H, s), 8.55(1H, dt, J=2.0, 8.0Hz), 8.70(1H, dd, J=2.0, 5.0Hz), 8.98(1H, d, J=2.0Hz).

Example 4

[0095] The procedure of Example 1 was repeated through use of 4-cyclopentylloxy-5-methoxy-2-pyridineacetonitrile (3a) and 4-pyridinecarbaldehyde, to thereby obtain the compound shown below.

[0096] (Z)-2-(4-Cyclopentylloxy-5-methoxy-2-pyridyl)-3-(4-pyridyl)propenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁶ = 4-pyridyl, and X = O)

Melting point: 142-142.5°C

¹H-NMR(CDCℓ₃) δ : 1.64-2.14(8H, m), 3.97(3H, s), 4.92-4.98(1H, m), 7.28(1H, s), 7.74(2H, dd, J=2.0.6.0Hz), 8.16(1H, s), 8.26(1H, s), 8.74(2H, dd, J=2.0, 6.0Hz).

Example 5

[0097] The procedure of Example 1 was repeated through use of 4-cyclopentylloxy-5-methoxy-2-pyridineacetonitrile (3a) and 2-methoxy-1-naphthaldehyde, to thereby obtain the compound shown below.

[0098] (Z)-2-(4-Cyclopentylloxy-5-methoxy-2-pyridyl)-3-(2-methoxy-1-naphthyl)propenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 2-methoxy-1-naphthyl, and X = O)

Melting point: 168-169°C

¹H-NMR(CDCℓ₃) δ : 1.60-2.15(8H, m), 3.97(3H, s), 4.04(3H, s), 4.80-5.00(1H, m), 7.29(1H, s), 7.34-7.42(2H, m), 7.48-7.53(1H, m), 7.80-7.93(3H, m), 8.21(1H, s), 8.69(1H, s).

Example 6

[0099] The procedure of Example 1 was repeated through use of 4-cyclopentylloxy-5-methoxy-2-pyridineacetonitrile (3a) and 2-chlorobenzaldehyde, to thereby obtain the compound shown below.

(Z)-3-(2-chlorophenyl)-2-(4-cyclopentylloxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 2-chlorophenyl, and X = O)

Melting point: 122-123°C

¹H-NMR(CDCℓ₃) δ : 1.60-2.15(8H, m), 3.96(3H, s), 4.92-4.97(1H, m), 7.26(1H, s), 7.35-7.41(2H, m), 7.46-7.50(1H, m), 8.10-8.18(1H, m), 8.19(1H, s), 8.63(1H, s).

Example 7

[0100] The procedure of Example 1 was repeated through use of 4-cyclopentylloxy-5-methoxy-2-pyridineacetonitrile (3a) and 4-cyanobenzaldehyde, to thereby obtain the compound shown below.

[0101] (Z)-3-(4-cyanophenyl)-2-(4-cyclopentylloxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 4-cyanophenyl, and X = O)

Melting point: 149-150°C

¹H-NMR(CDCl₃) δ : 1.55-2.20(8H, m), 3.97(3H, s), 4.80-5.10(1H, m), 7.28(1H, s), 7.75(2H, d, J=9.0Hz), 8.03(2H, d, J=9.0Hz), 8.15(1H, s), 8.33(1H, s).

Example 8

[0102] The procedure of Example 1 was repeated through use of 4-cyclopentylloxy-5-methoxy-2-pyridineacetonitrile (3a) and 4-trifluoromethylbenzaldehyde, to thereby obtain the compound shown below.

(Z)-2-(4-Cyclopentylloxy-5-methoxy-2-pyridyl)-3-(4-trifluoromethylphenyl) propenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 4-trifluoromethylphenyl, and X = O)

Melting point: 116-117°C

¹H-NMR(CDCl₃) δ : 1.55-2.20(8H, m), 3.97(3H, s), 4.80-5.10(1H, m), 7.27(1H, s), 7.72(2H, d, J=9.0Hz), 8.04(2H, d, J=9.0Hz), 8.15(1H, s), 8.35(1H, s).

Example 9

[0103] The procedure of Example 1 was repeated through use of 4-cyclopentylloxy-5-methoxy-2-pyridineacetonitrile (3a) and 2,6-dimethoxybenzaldehyde, to thereby obtain the compound shown below.

[0104] (Z)-2-(4-Cyclopentylloxy-5-methoxy-2-pyridyl)-3-(2,6-dimethoxyphenyl)propenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 2,6-dimethoxyphenyl, and X = O)

Melting point: 168-170°C

¹H-NMR(CDCl₃) δ : 1.55-2.10(8H, m), 3.89(6H, s), 3.94(3H, s), 4.80-5.10(1H, m), 6.60(2H, d, J=8.0Hz), 7.24(1H, s), 7.42(1H, t, J=8.0Hz), 8.16(1H, s), 8.27(1H, s).

Example 10

[0105] The procedure of Example 1 was repeated through use of 4-cyclopentylloxy-5-methoxy-2-pyridineacetonitrile (3a) and 4-quinolinecarbaldehyde, to thereby obtain the compound shown below.

(Z)-2-(4-Cyclopentylloxy-5-methoxy-2-pyridyl)-3-(4-quinolyl)propenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 4-quinolyl, and X = O)

Melting point: 160-161°C

¹H-NMR(CDCl₃) δ : 1.55-2.10(8H, m), 4.00(3H, s), 4.80-5.10(1H, m), 7.32(1H, s), 7.45-8.30(5H, m), 8.21(1H, s), 9.02(1H, s), 9.04(1H, d, J=4.0Hz).

Example 11

[0106] The procedure of Example 1 was repeated through use of 4-cyclopentylloxy-5-methoxy-2-pyridineacetonitrile (3a) and 3,5-dimethoxy-4-pyridinecarbaldehyde (Preparation Example 8), to thereby obtain the compound shown below.

(Z)-2-(4-Cyclopentylloxy-5-methoxy-2-pyridyl)-3-(3,5-dimethoxy-4-pyridyl)propenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dimethoxy-4-pyridyl, and X = O)

Melting point: 143-144°C

¹H-NMR(CDCl₃) δ : 1.55-2.10(8H, m), 3.96(3H, s), 4.00(6H, s), 4.80-5.10(1H, m), 7.25(1H, s), 8.11(2H, s), 8.17(2H, s).

Example 12

[0107] The procedure of Example 1 was repeated through use of 4-cyclopentyloxy-5-methoxy-2-pyridineacetonitrile (3a) and benzaldehyde, to thereby obtain the compound shown below.

(Z)-2-(4-Cyclopentyloxy-5-methoxy-2-pyridyl)-3-phenylpropenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = phenyl, and X = O)

Melting point: 107-108°C

¹H-NMR(CDCl₃) δ : 1.40-2.30(8H, m), 3.96(3H, s), 4.80-5.10(1H, m), 7.26(1H, s), 7.35-7.60(3H, m), 7.80-8.10(2H, m), 8.15(1H, s), 8.32(1H, s).

Example 13

[0108] The procedure of Example 1 was repeated through use of 4-cyclopentyloxy-5-methoxy-2-pyridineacetonitrile (3a) and 2-thiophenecarbaldehyde, to thereby obtain the compound shown below.

(Z)-2-(4-Cyclopentyloxy-5-methoxy-2-pyridyl)-3-(2-thienyl)propenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 2-thienyl, and X = O)

Melting point: 89-90°C

¹H-NMR(CDCl₃) δ : 1.60-2.20(8H, m), 3.95 (3H, s), 4.80-5.00(1H, m), 7.05-7.25(1H, m), 7.19(1H, s), 7.57(1H, d, J=5.0Hz), 7.72(1H, d, J=4.0Hz), 8.12(1H, s), 8.44(1H, s).

Example 14

[0109] The procedure of Example 1 was repeated through use of 5-methoxy-4-phenethyloxy-2-pyridineacetonitrile (3c) and 3,5-dichloro-4-pyridinecarbaldehyde (Preparation Example 7), to thereby obtain the compound shown below.

(Z)-3-(3,5-Dichloro-4-pyridyl)-2-(5-methoxy-4-phenethyloxy-2-pyridyl)propenenitrile (formula (1), wherein R¹ = phenethyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O)

Melting point: 141.5-142.5°C

¹H-NMR(CDCl₃) δ : 3.21(2H, t, J=8.0Hz), 4.00(3H, s), 4.34(2H, t, J=8.0Hz), 7.20-7.40(6H, m), 8.16(1H, s), 8.22(1H, s), 8.60(2H, s).

Example 15

[0110] The procedure of Example 1 was repeated through use of 5-methoxy-4-(3-phenylpropyloxy)-2-pyridineacetonitrile (3d) and 3,5-dichloro-4-pyridinecarbaldehyde (Preparation Example 7), to thereby obtain the compound shown below.

(Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-4-(3-phenylpropyloxy)-2-pyridyl]propenenitrile (formula (1), wherein R¹ = 3-phenylpropyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O)

Melting point: 101-102°C

¹H-NMR(CDCl₃) δ : 2.00-2.40(2H, m), 2.86(2H, t, J=8.0Hz), 4.02(3H, s), 4.15(2H, t, J=8.0Hz), 7.10-7.40(6H, m), 8.16(1H, s), 8.22(1H, s), 8.60(2H, s).

Example 16

[0111] The procedure of Example 1 was repeated through use of 4-butyloxy-5-methoxy-2-pyridineacetonitrile (3e) and 3,5-dichloro-4-pyridinecarbaldehyde (Preparation Example 7), to thereby obtain the compound shown below.

(Z)-2-(4-Butyloxy-5-methoxy-2-pyridyl)-3-(3,5-dichloro-4-pyridyl)propenenitrile (formula (1), wherein R¹ = butyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O)

Melting point: 108-109°C

¹H-NMR(CDCl₃) δ : 1.00(3H, t, J=7.0Hz), 1.30-2.10(4H, m), 4.00(3H, s), 4.16(2H, t, J=7.0Hz), 7.27(1H, s), 8.19(1H, s), 8.21(1H, s), 8.61(2H, s).

Example 17

[0112] The procedure of Example 1 was repeated through use of 4-(1-ethylpropyloxy)-5-methoxy-2-pyridineacetonitrile (3f) and 3,5-dichloro-4-pyridinecarbaldehyde (Preparation Example 7), to thereby obtain the compound shown below.

[0113] (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[4-(1-ethylpropyloxy)-5-methoxy-2-pyridyl]propenenitrile (formula (1), wherein $R^1 = 1\text{-ethylpropyl}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$)

Melting point: 127-127.5°C

$^1\text{H-NMR}(\text{CDCl}_3) \delta$: 1.00(6H, t, $J=7.0\text{Hz}$), 1.60-2.00(4H, m), 4.00(3H, s), 4.10-4.40(1H, m), 7.25(1H, s), 8.19(1H, s), 8.22(1H, s), 8.61(2H, s).

Example 18

[0114] The procedure of Example 1 was repeated through use of 4-cyclopentyloxy-5-ethoxy-2-pyridineacetonitrile (3d) and 3,5-dichloro-4-pyridinecarbaldehyde (Preparation Example 7), to thereby obtain the compound shown below.

(Z)-2-(4-Cyclopentyloxy-5-ethoxy-2-pyridyl)-3-(3,5-dichloro-4-pyridyl)propenenitrile (formula (1), wherein $R^1 = \text{cyclopentyl}$, $R^2 = \text{C}_2\text{H}_5$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$)

Melting point: 90-91°C

$^1\text{H-NMR}(\text{CDCl}_3) \delta$: 1.46(3H, t, $J=7.0\text{Hz}$), 1.60-2.20(8H, m), 4.19(2H, q, $J=7.0\text{Hz}$), 4.80-5.00(1H, m), 7.26(1H, s), 8.18(1H, s), 8.19(1H, s), 8.61(2H, s).

Example 19

[0115] The procedure of Example 1 was repeated through use of 4-(2-indanyloxy)-5-methoxy-2-pyridineacetonitrile (3h) and 3,5-dichloro-4-pyridinecarbaldehyde (Preparation Example 7), to thereby obtain the compound shown below.

[0116] (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[4-(2-indanyloxy)-5-methoxy-2-pyridyl]propenenitrile (formula (1), wherein $R^1 = 2\text{-indanyl}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$)

Melting point: 185-185.5°C

$^1\text{H-NMR}(\text{CDCl}_3) \delta$: 3.28(2H, dd, $J=3.5, 17.0\text{Hz}$), 3.51(2H, dd, $J=6.0, 17.0\text{Hz}$), 3.92(3H, s), 5.32-5.38(1H, m), 7.17-7.28(5H, m), 8.21(1H, s), 8.22(1H, s), 8.61(2H, s).

Example 20

[0117] The procedure of Example 1 was repeated through use of 5-methoxy-4-(tetrahydro-3-furanyloxy)-2-pyridineacetonitrile (3j) and 3,5-dichloro-4-pyridinecarbaldehyde (Preparation Example 7), to thereby obtain the compound shown below.

[0118] (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-4-(tetrahydro-3-furanyloxy)-2-pyridyl]propenenitrile (formula (1), wherein $R^1 = \text{tetrahydro-3-furanyl}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$)

Melting point: 138-140°C

$^1\text{H-NMR}(\text{CDCl}_3) \delta$: 2.10-2.50(2H, m), 3.80-4.20(4H, m), 3.99(3H, s), 5.00-5.20(1H, m), 7.20(1H, s), 8.21(1H, s), 8.24(1H, s), 8.61(2H, s).

Example 21

[0119] The procedure of Example 1 was repeated through use of 5-methoxy-4-(exo-2-norbornyloxy)-2-pyridineacetonitrile (3i) and 3,5-dichloro-4-pyridinecarbaldehyde (Preparation Example 7), to thereby obtain the compound shown below.

[0120] (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-4-(exo-2-norbornyloxy)-2-pyridyl]propenenitrile (formula (1), wherein $R^1 = \text{exo-2-norbornyl}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$)

Melting point: 145.5-146.5°C

$^1\text{H-NMR}(\text{CDCl}_3) \delta$: 1.10-2.00(8H, m), 2.30-2.70(2H, m), 3.98(3H, s), 4.30-4.50(1H, m), 7.21(1H, s), 8.19(2H, s), 8.61(2H, s).

Example 22

Synthesis of methyl (E)-2-(4-cyclopentyloxy-5-methoxy-2-pyridyl)-3-(3,5-dichloro-4-pyridyl)propenoate (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = CO₂CH₃, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O) :

[0121] Under the same conditions in Example 1 and through use of methyl 4-cyclopentyloxy-5-methoxy-2-pyridineacetate (3k) and 3,5-dichloro-4-pyridinecarbaldehyde (Preparation Example 7) in methanol containing a CH₃ONa-CH₃OH solution (1 M), the title compound was prepared.

Melting point: 119-120°C
¹H-NMR(CDCℓ₃) δ : 1.55-1.90(8H, m), 3.86(3H, s), 3.91(3H, s), 4.56-4.60(1H, m), 6.70(1H, s), 7.57(1H, s), 7.94(1H, s), 8.40(2H, s).

Reference Example 1

Synthesis of (Z)-3-(4-cyclopentyloxy-5-methoxy-2-pyridyl)-2-(3-pyridyl)propenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = H, R⁴ = CN, R⁵ = 3-pyridyl, and X = O) :

[0122] 4-Cyclopentyloxy-5-methoxy-2-pyridinecarbaldehyde (4.42 g, 20 mmol) and 3-pyridineacetonitrile (2.36 g, 20 mmol) were dissolved in methanol (60 ml). While the solution was stirred at 5°C, a CH₃ONa-CH₃OH solution (1 M, 23 ml) was added dropwise. The mixture was stirred for 30 additional minutes under the same condition. The reaction mixture was poured into cold water and extracted with chloroform. The organic layer was dried and then concentrated under reduced pressure. The residue was chromatographed on silica gel, to thereby obtain the title compound (4.54 g, yield 71%) from a 1% (v/v) methanol-chloroform-eluted fraction.

Melting point: 119-119.5°C
¹H-NMR(CDCℓ₃) δ : 1.60-2.20(8H, m), 4.00(3H, s), 4.92-4.98(1H, m), 7.41(1H, dd, J=5.0, 7.0Hz), 7.64(1H, s), 7.72(1H, s), 7.98-8.03(1H, m), 8.26(1H, s), 8.64(1H, dd, J=1.5, 5.0Hz), 8.97(1H, d, J=2.0Hz).

Reference Example 2

[0123] The procedure of Reference Example 1 was repeated through use of 4-cyclopentyloxy-5-methoxy-2-pyridinecarbaldehyde and 2-thiopheneacetonitrile, to thereby obtain the compound shown below.

(Z)-3-(4-Cyclopentyloxy-5-methoxy-2-pyridyl)-2-(2-thienyl)propenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = H, R⁴ = CN, R⁵ = 2-thienyl, and X = O).

Melting point: 101-102°C
¹H-NMR(CDCℓ₃) δ : 1.60-2.15(8H, m), 3.98(3H, s), 4.92-4.98(1H, m), 7.08(1H, dd, J=4.0, 5.0Hz), 7.33(1H, dd, J=1.0, 5.0Hz), 7.43(1H, s), 7.44(1H, dd, J=1.0, 4.0Hz), 7.62(1H, s), 8.22(1H, s).

Reference Example 3

[0124] The procedure of Reference Example 1 was repeated through use of 4-cyclopentyloxy-5-methoxy-2-pyridinecarbaldehyde and phenylacetonitrile, to thereby obtain the compound shown below.

(Z)-3-(4-Cyclopentyloxy-5-methoxy-2-pyridyl)-2-phenylpropenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = H, R⁴ = CN, R⁵ = phenyl, and X = O).

Melting point: 91-91.5°C
¹H-NMR(CDCℓ₃) δ : 1.60-2.20(8H, m), 3.99(3H, s), 4.92-4.98(1H, m), 7.38-7.49(3H, m), 7.62(1H, s), 7.70-7.75(2H, m), 7.77(1H, s), 8.23(1H, s).

Example 23

[0125] The procedure of Example 1 was repeated through use of 5-methoxy-4-methoxymethoxy-2-pyridineacetonitrile (3g) and 3,5-dichloro-4-pyridinecarbaldehyde (Preparation Example 7), to thereby obtain the compound shown below.

(Z)-3-(3,5-Dichloro-4-pyridyl)-2-(5-methoxy-4-methoxymethoxy-2-pyridyl)propenenitrile (formula (1), wherein

$R^1 = \text{CH}_2\text{OCH}_3$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$).

Melting point: 140-141°C

$^1\text{H-NMR}(\text{CDCl}_3) \delta$: 3.54(3H, s), 4.03(3H, s), 5.38(2H, s), 7.54(1H, s), 8.14(1H, s), 8.28(1H, s), 8.61(2H, s).

Example 24

Synthesis of (Z)-3-(3,5-dichloro-4-pyridyl)-2-(4-hydroxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein $R^1 = \text{H}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$):

[0126] In 8 ml of dichloromethane, was dissolved (Z)-3-(3,5-dichloro-4-pyridyl)-2-(5-methoxy-4-methoxymethoxy-2-pyridyl)propenenitrile (formula (1), wherein $R^1 = \text{CH}_2\text{OCH}_3$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$) (0.73 g, 2 mmol). While the solution was stirred at 0°C, trifluoroacetic acid (2 ml) was added. The mixture was stirred for additional two hours. The reaction mixture was evaporated to dryness. The residue was dissolved through addition of water, and the pH of the solution was adjusted to about 6 through addition of an aqueous saturated sodium hydrogencarbonate solution. Precipitated crystals were collected by filtration, washed with water, and recrystallized from ethanol, to thereby obtain the title compound (0.56 g, yield 88%).

Melting point: 218-219.5°C

$^1\text{H-NMR}(\text{DMSO-d}_6) \delta$: 3.94(3H, s), 7.33(1H, s), 8.19(1H, s), 8.29(1H, s), 8.81(2H, s).

Example 25

Synthesis of (Z)-3-(3,5-dichloro-4-pyridyl)-2-(4-(3-hydroxypropyloxy)-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein $R^1 = (\text{CH}_2)_3\text{OH}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$):

[0127] In 4 ml of dimethylformamide, was dissolved (Z)-3-(3,5-dichloro-4-pyridyl)-2-(4-hydroxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein $R^1 = \text{H}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$) (400 mg, 1.24 mmol). To the solution were added 3-bromopropanol (0.132 ml, 1.48 mmol) and potassium carbonate (204 mg, 1.48 mmol). The mixture was stirred on a 60°C oil bath for three hours. After being cooled, the reaction mixture was poured into cold water and extracted with in ethyl acetate. The organic layer was sequentially washed with water and saturated brine, dried, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography. Crystals obtained from the 1% hexane-ethyl acetate (1 : 1)-eluted fraction were recrystallized from hexane-diethyl ether, to thereby obtain the title compound (360 mg, yield 76%).

Melting point: 111-113°C

$^1\text{H-NMR}(\text{CDCl}_3) \delta$: 1.94(1H, t, $J=5.0\text{Hz}$), 2.12-2.20(2H, m), 3.87-3.92(2H, m), 4.00(3H, s), 4.33(2H, t, $J=6.0\text{Hz}$), 7.30(1H, s), 8.13(1H, s), 8.22(1H, s), 8.61(2H, s).

Example 26

[0128] The procedure of Example 1 was repeated through use of 4-cyclopentylthio-5-methoxy-2-pyridineacetonitrile (10a) and 3,5-dichloro-4-pyridinecarbaldehyde (Preparation Example 7), to thereby obtain the compound shown below.

[0129] (Z)-2-(4-Cyclopentylthio-5-methoxy-2-pyridyl)-3-(3,5-dichloro-4-pyridyl)propenenitrile (formula (1), wherein $R^1 = \text{cyclopentyl}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{S}$).

Melting point: 147-148°C

$^1\text{H-NMR}(\text{CDCl}_3) \delta$: 1.50-2.40(8H, m), 3.60-3.95(1H, m), 4.04(3H, s), 7.59(1H, s), 8.14(1H, s), 8.18(1H, s), 8.61(2H, s).

Reference Example 4

[0130] The procedure of Reference Example 1 was repeated through use of 4-cyclopentylthio-5-methoxy-2-pyridinecarbaldehyde and 3,5-dichloro-4-pyridineacetonitrile, to thereby obtain the compound shown below.

[0131] (Z)-3-(4-Cyclopentylthio-5-methoxy-2-pyridyl)-2-(3,5-dichloro-4-pyridyl)propenenitrile (formula (1), wherein $R^1 = \text{cyclopentyl}$, $R^2 = \text{CH}_3$, $R^3 = \text{H}$, $R^4 = \text{CN}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$).

Melting point: 140.5-142°C

¹H-NMR(CDCl₃) δ : 1.50-2.00(8H, m), 3.88(3H, s), 4.50-4.70(1H, m), 6.68(1H, s), 7.51(1H, s), 7.89(1H, s), 8.57(2H, s).

Example 27

Synthesis of (E)-2-(4-cyclopentyloxy-5-methoxy-2-pyridyl)-3-(3,5-dichloro-4-pyridyl)propenoic acid (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = CO₂H, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O) :

[0132] Methyl (E)-2-(4-cyclopentyloxy-5-methoxy-2-pyridyl)-3-(3,5-dichloro-4-pyridyl)propenoate (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = CO₂CH₃, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O) (423 mg, 1 mmol) was dissolved in methanol (4 ml). A 1N aqueous NaOH solution (2 ml) was added to the solution. The mixture was stirred for two hours at room temperature and the reaction mixture was poured into a 5% aqueous ammonium chloride solution. Precipitated crystals were collected by filtration, washed, and recrystallized from ethanol, to thereby obtain the title compound (240 mg, yield 59%).

Melting point: 178-180°C (decomposition)

¹H-NMR(CDCl₃) δ : 1.40-2.00(8H, m), 3.77(3H, s), 4.58-4.80(1H, m), 6.78(1H, s), 7.50(1H, s), 7.94(1H, s), 8.56(2H, s).

Example 28

[0133] The procedure of Example 1 was repeated through use of 4-cyclopentyloxy-5-methoxy-2-pyridineacetonitrile (3a) and 3-nitrobenzaldehyde, to thereby obtain the compound shown below.

[0134] (Z)-2-(4-Cyclopentyloxy-5-methoxy-2-pyridyl)-3-(3-nitrophenyl)propenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3-nitrophenyl, and X = O).

Melting point: 126-127°C

¹H-NMR(CDCl₃) δ : 1.50-2.20(8H, m), 3.98(3H, s), 4.82-5.10(1H, m), 7.28(1H, s), 7.67(1H, t, J=8.0Hz), 8.16(1H, s), 8.20-8.40(3H, m), 8.60-8.70(1H, m).

Example 29

[0135] The procedure of Example 1 was repeated through use of 4-cyclopentyloxy-5-methoxy-2-pyridineacetonitrile (3a) and 3-fluoro-4-pyridinecarbaldehyde (Preparation Example 12), to thereby obtain the compound shown below.

[0136] (Z)-2-(4-Cyclopentyloxy-5-methoxy-2-pyridyl)-3-(3-fluoro-4-pyridyl)propenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3-fluoro-4-pyridyl, and X = O).

Melting point: 120-121°C

¹H-NMR(CDCl₃) δ : 1.60-2.15(8H, m), 3.98(3H, s), 4.92-4.97(1H, m), 7.28(1H, s), 8.10(1H, t, J=6.0Hz), 8.18(1H, s), 8.47(1H, s), 8.56(1H, d, J=5Hz), 8.60(1H, d, J=2Hz).

Example 30

[0137] The procedure of Example 1 was repeated through use of 4-(2-indanyloxy)-5-methoxy-2-pyridineacetonitrile (3h) and methyl 4-formyl-2-picolinate, to thereby obtain the compound shown below.

[0138] (Z)-2-[4-(2-Indanyloxy)-5-methoxy-2-pyridyl]-3-(2-methoxycarbonyl-4-pyridyl)propenenitrile (formula (1), wherein R¹ = 2-indanyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 2-methoxycarbonyl-4-pyridyl, and X = O).

Melting point: 177-179°C

¹H-NMR(CDCl₃) δ : 3.14-3.85(4H, m), 3.93(3H, s), 4.05(3H, s), 5.29-5.36(1H, m), 7.24-7.37(5H, m), 8.01-8.09(1H, m), 8.18(1H, s), 8.35(1H, s), 8.47(1H, s), 8.89(1H, d, J=5.0Hz).

Example 31

[0139] The procedure of Example 1 was repeated through use of 4-(2-indanyloxy)-5-methoxy-2-pyridineacetonitrile (3h) and 4-pyridinecarbaldehyde, to thereby obtain the compound shown below.

[0140] (Z)-2-[4-(2-Indanyloxy)-5-methoxy-2-pyridyl]-3-(4-pyridyl)propenenitrile (formula (1), wherein R¹ = 2-indanyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 4-pyridyl, and X = O).

Melting point: 205-206°C
¹H-NMR(CDCℓ₃) δ : 3.15-3.75(4H, m), 3.92(3H, s), 5.20-5.50(1H, m), 7.24(4H, s), 7.36(1H, s), 7.75(2H, d, J=7.0Hz), 8.17(1H, s), 8.28(1H, s), 8.78(2H, d, J=7.0Hz).

5 Example 32

[0141] The procedure of Example 1 was repeated through use of 4-(2-indanyloxy)-5-methoxy-2-pyridineacetonitrile (3h) and 4-pyridinecarbaldehyde N-oxide, to thereby obtain the compound shown below.

[0142] 4-[(Z)-2-Cyano-2-(4-(2-indanyloxy)-5-methoxy-2-pyridyl)-1-ethenyl]pyridine N-oxide (formula (1), wherein R¹ = 2-indanyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 2-oxo-4-pyridyl, and X = O).

Melting point: 231-232°C
¹H-NMR(CDCℓ₃) δ : 3.15-3.72(4H, m), 3.92(3H, s), 5.20-5.45(1H, m), 7.24 (4H, s), 7.33(1H, s), 7.85(2H, d, J=7.0Hz), 8.10-8.30(4H, m).

15 Example 33

[0143] The procedure of Example 1 was repeated through use of 4-(2-indanyloxy)-5-methoxy-2-pyridineacetonitrile (3h) and 3,5-dichloro-4-pyridinecarbaldehyde N-oxide (Preparation Example 13), to thereby obtain the compound shown below.

[0144] 4-[(Z)-2-Cyano-2-(4-(2-indanyloxy)-5-methoxy-2-pyridyl)-1-ethenyl]-3,5-dichloropyridine N-oxide (formula (1), wherein R¹ = 2-indanyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-1-oxo-4-pyridyl, and X = O).

Melting point: 229-230°C
¹H-NMR(CDCℓ₃) δ : 3.10-3.72(4H, m), 3.93(3H, s), 5.20-5.43(1H, m), 7.23(5H, s), 8.13(1H, s), 8.20(1H, s), 8.26 (2H, s).

Example 34

[0145] Synthesis of (Z)-3-(3-carboxyphenyl)-2-(4-cyclopentyloxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3-carboxyphenyl, and X = O) :

[0145] 4-Cyclopentyloxy-5-methoxy-2-pyridineacetonitrile (3a) (4.64 g, 20 mmol) and 3-formylbenzoic acid (3.00 g, 20 mmol) were dissolved in methanol (60 ml). While the solution was stirred at 5°C, 1 M aqueous CH₃ONa-CH₃OH solution (46 ml) was added dropwise. The reaction mixture was stirred for 30 minutes under the same conditions and was poured into a 5% aqueous ammonium chloride solution. Precipitated crystals were collected by filtration, washed, and recrystallized from ethanol, to thereby obtain the title compound (4.00 g, yield 55%).

Melting point: 253-254°C
¹H-NMR(DMSO-d₆) δ : 1.50-2.20(8H, m), 3.90(3H, s), 4.98-5.20(1H, m), 7.49(1H, s), 7.67(1H, t, J=7.5Hz), 8.00-8.30(2H, m), 8.25(1H, s), 8.35(1H, s), 8.56(1H, s).

Reference Example 5

[0146] The procedure of Reference Example 1 was repeated through use of 4-cyclopentyloxy-5-methoxy-2-pyridinecarbaldehyde and methyl 3-cyanomethylbenzoate, to thereby obtain the compound shown below.

[0147] (Z)-3-(4-Cyclopentyloxy-5-methoxy-2-pyridyl)-2-(3-methoxycarbonylphenyl)propenenitrile (formula (1), wherein R¹ = cyclopentyl, R² = CH₃, R³ = H, R⁴ = CN, R⁵ = 3-methoxycarbonylphenyl, and X = O).

Melting point: 116-117°C
¹H-NMR(CDCℓ₃) δ : 1.55-2.30(8H, m), 3.96(3H, s), 4.00(3H, s), 4.80-5.10(1H, m), 7.42-8.50(7H, m).

Reference Example 6

[0148] The procedure of Reference Example 1 was repeated through use of 4-(2-indanyloxy)-5-methoxy-2-pyridinecarbaldehyde (Preparation Example 14) and methyl 3-cyanomethylbenzoate, to thereby obtain the compound shown below.

[0149] (Z)-3-[4-(2-Indanyloxy)-5-methoxy-2-pyridyl]-2-(3-methoxycarbonylphenyl)propenenitrile (formula (1),

wherein $R^1 = 2\text{-indanyl}$, $R^2 = \text{CH}_3$, $R^3 = \text{H}$, $R^4 = \text{CN}$, $R^5 = 3\text{-methoxycarbonylphenyl}$, and $X = \text{O}$).

Melting point: 183-184°C

$^1\text{H-NMR}(\text{DMSO-}d_6) \delta$: 3.10-3.70(4H, m), 3.94(3H, s), 3.96(3H, s), 5.20-5.40(1H, m), 7.23(4H, s), 7.40-8.40(7H, m)

Reference Example 7

[0150] The procedure of Reference Example 1 was repeated through use of 4-(2-indanyloxy)-5-methoxy-2-pyridinecarbaldehyde (Preparation Example 14) and 4-pyridineacetonitrile, to thereby obtain the compound shown below.

[0151] (Z)-3-[4-(2-Indanyloxy)-5-methoxy-2-pyridyl]-2-(4-pyridyl)propenenitrile (formula (1), wherein $R^1 = 2\text{-indanyl}$, $R^2 = \text{CH}_3$, $R^3 = \text{H}$, $R^4 = \text{CN}$, $R^5 = 4\text{-pyridyl}$, and $X = \text{O}$).

Melting point: 195-197°C

$^1\text{H-NMR}(\text{CDCl}_3) \delta$: 3.10-3.75(4H, m), 3.96(3H, s), 5.20-5.45(1H, m), 7.23(4H, s), 7.62(2H, d, $J=6.0\text{Hz}$), 7.82(1H, s), 7.87(1H, s), 8.29(1H, s), 8.73(2H, d, $J=6.0\text{Hz}$).

Example 35

[0152] The procedure of Example 25 was repeated through use of (Z)-3-(3,5-dichloro-4-pyridyl)-2-(4-hydroxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein $R^1 = \text{H}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$) and methyl bromoacetate, to thereby obtain the compound shown below.

[0153] (Z)-3-(3,5-Dichloro-4-pyridyl)-2-(5-methoxy-4-methoxycarbonylmethoxy-2-pyridyl)propenenitrile (formula (1), wherein $R^1 = \text{CH}_2\text{CO}_2\text{CH}_3$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$).

Melting point: 131-132°C

$^1\text{H-NMR}(\text{CDCl}_3) \delta$: 3.85(3H, s), 4.04(3H, s), 4.84(2H, s), 7.14(1H, s), 8.19(1H, s), 8.27(1H, s), 8.61(2H, s).

Example 36

[0154] The procedure of Example 25 was repeated through use of (Z)-3-(3,5-dichloro-4-pyridyl)-2-(4-hydroxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein $R^1 = \text{H}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$) and 2-bromoethanol, to thereby obtain the compound shown below.

[0155] (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[4-(2-hydroxyethoxy)-5-methoxy-2-pyridyl]propenenitrile (formula (1), wherein $R^1 = (\text{CH}_2)_2\text{OH}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$).

Melting point: 159-160°C

$^1\text{H-NMR}(\text{CDCl}_3) \delta$: 2.24(1H, t, $J=6.0\text{Hz}$), 4.01(3H, s), 4.04-4.08(2H, m), 4.27(2H, t, $J=4.0\text{Hz}$), 7.29(1H, s), 8.19(1H, s), 8.24(1H, s), 8.61(2H, s).

Example 37

[0156] The procedure of Example 25 was repeated through use of (Z)-3-(3,5-dichloro-4-pyridyl)-2-(4-hydroxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein $R^1 = \text{H}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$) and 4-bromobutanol, to thereby obtain the compound shown below.

[0157] (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[4-(4-hydroxybutyloxy)-5-methoxy-2-pyridyl]propenenitrile (formula (1), wherein $R^1 = (\text{CH}_2)_4\text{OH}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$).

Melting point: 120.5-122°C

$^1\text{H-NMR}(\text{CDCl}_3) \delta$: 1.74-1.82(3H, m), 1.99-2.05(2H, m), 3.75(2H, m), 4.00(3H, s), 4.21 (2H, t, $J=6.0\text{Hz}$), 7.27(1H, s), 8.19(1H, s), 8.21(1H, s), 8.61(2H, s).

Example 38

[0158] The procedure of Example 25 was repeated through use of (Z)-3-(3,5-dichloro-4-pyridyl)-2-(4-hydroxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein $R^1 = \text{H}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$) and 5-bromopentanol, to thereby obtain the compound shown below.

[0159] (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[4-(5-hydroxypentyloxy)-5-methoxy-2-pyridyl]propenenitrile (formula (1), wherein $R^1 = (\text{CH}_2)_5\text{OH}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$).

Melting point: 86-87°C
¹H-NMR(CDC₃) δ: 1.35(1H, m), 1.58-1.70(4H, m), 1.93-1.97(2H, m), 3.71 (2H, m), 4.00(3H, s), 4.16(2H, t, J=6.0Hz), 7.26(1H, s), 8.19(1H, s), 8.21 (1H, s), 8.61 (2H, s).

5 Example 39

Synthesis of (Z)-3-(3,5-dichloro-4-pyridyl)-2-[5-methoxy-4-(3,4-methylenedioxyphenylmethoxy)-2-pyridyl]propenenitrile (formula (1), wherein R¹ = 3,4-methylenedioxyphenylmethyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O) :

10

[0160] (Z)-3-(3,5-Dichloro-4-pyridyl)-2-(4-hydroxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein R¹ = H, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O) (0.97 g, 3.0 mmol), 3,4-methylenedioxyphenylmethanol (0.50 g, 3.3 mmol), and triphenylphosphine (1.18 g, 4.5 mmol) were dissolved in tetrahydrofuran (100 ml). While the solution was stirred at room temperature, diethyl azodicarboxylate (0.78 g, 4.5 mmol) was added dropwise. The reaction mixture was stirred for four hours at room temperature and then water was added thereto. The mixture was extracted with ethyl acetate. The organic layer was sequentially washed with water and saturated brine, dried, and then concentrated under reduced pressure. Crystals precipitated from the residue were recrystallized from an isopropyl ether-ethanol, to thereby obtain the title compound (1.01 g, yield 74%).

15

20

Melting point: 182-183°C
¹H-NMR(CDC₃) δ: 4.00(3H, s), 5.15(2H, s), 5.98(2H, s), 6.80-7.00(3H, m), 7.36(1H, s), 8.16(1H, s), 8.23(1H, s), 8.61(2H, s).

Example 40

25

[0161] The procedure of Example 39 was repeated through use of (Z)-3-(3,5-dichloro-4-pyridyl)-2-(4-hydroxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein R¹ = H, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O) and 4,5-dimethoxy-2-pyridinemethanol, to thereby obtain the compound shown below.

30

[0162] (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[4-(4,5-dimethoxy-2-pyridylmethoxy)-5-methoxy-2-pyridyl]propenenitrile (formula (1), wherein R¹ = 4,5-dimethoxy-2-pyridylmethyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O).

35

Melting point: 146.5-147.5°C
¹H-NMR(CDC₃) δ: 3.94(3H, s), 3.96(3H, s), 4.03(3H, s), 5.31(2H, s), 7.07(1H, s), 7.52(1H, s), 8.09(1H, s), 8.14 (1H, s), 8.24(1H, s), 8.60(2H, s).

Example 41

40

[0163] The procedure of Example 39 was repeated through use of (Z)-3-(3,5-dichloro-4-pyridyl)-2-(4-hydroxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein R¹ = H, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O) and cyclopropanemethanol, to thereby obtain the compound shown below.

[0164] (Z)-2-(4-Cyclopropylmethoxy-5-methoxy-2-pyridyl)-3-(3,5-dichloro-4-pyridyl)propenenitrile (formula (1), wherein R¹ = cyclopropylmethyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3, 5-dichloro-4-pyridyl, and X = O).

45

Melting point: 118-119°C
¹H-NMR(CDC₃) δ: 0.44(2H, m), 0.72(2H, m), 1.36(1H, m), 3.99(2H, d, J=7.5Hz), 4.02(3H, s), 7.7.23(1H, s), 8.19 (1H, s), 8.23(1H, s), 8.61(2H, s).

Example 42

50

[0165] The procedure of Example 39 was repeated through use of (Z)-3-(3,5-dichloro-4-pyridyl)-2-(4-hydroxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein R¹ = H, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O) and 2-pyridineethanol, to thereby obtain the compound shown below.

55

[0166] (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-4-(2-(2-pyridyl)ethoxy)-2-pyridyl]propenenitrile (formula (1), wherein R¹ = 2-(2-pyridyl)ethyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O).

Melting point: 134-135°C
¹H-NMR(CDC₃) δ: 3.38(2H, t, J=7.0Hz), 3.96(3H, s), 4.58(2H, t, J=7.0Hz), 7.00-7.30(2H, m), 7.32(1H, s), 7.65

(1H, m), 8.15 (1H, s), 8.21(1H, s), 8.55(1H, m), 8.61 (2H, s).

Example 43

[0167] The procedure of Example 39 was repeated through use of (Z)-3-(3,5-dichloro-4-pyridyl)-2-(4-hydroxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein $R^1 = H$, $R^2 = CH_3$, $R^3 = CN$, $R^4 = H$, $R^5 = 3,5$ -dichloro-4-pyridyl, and $X = O$) and 4-methyl-5-thiazoleethanol, to thereby obtain the compound shown below.

[0168] (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-4-(2-(4-methyl-5-thiazolyl)ethoxy)-2-pyridyl]propenenitrile (formula (1), wherein $R^1 = 2$ -(4-methyl-5-thiazolyl)ethyl, $R^2 = CH_3$, $R^3 = CN$, $R^4 = H$, $R^5 = 3,5$ -dichloro-4-pyridyl, and $X = O$).

Melting point: 136-137°C

1H -NMR(CDC ℓ_3) δ : 2.48(3H, s), 3.36(2H, t, $J=7.0$ Hz), 4.00(3H, s), 4.31(2H, t, $J=7.0$ Hz), 7.22(1H, s), 8.18(1H, s), 8.23(1H, s), 8.61(2H, s), 8.61(1H, s).

Example 44

[0169] The procedure of Example 39 was repeated through use of (Z)-3-(3,5-dichloro-4-pyridyl)-2-(4-hydroxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein $R^1 = H$, $R^2 = CH_3$, $R^3 = CN$, $R^4 = H$, $R^5 = 3,5$ -dichloro-4-pyridyl, and $X = O$) and N-hydroxyethyl-2-pyridone (Preparation Example 15), to thereby obtain the compound shown below.

[0170] (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-4-(2-(2-pyridon-1-yl)ethoxy)-2-pyridyl]propenenitrile (formula (1), wherein $R^1 = 2$ -(2-pyridon-1-yl)ethyl, $R^2 = CH_3$, $R^3 = CN$, $R^4 = H$, $R^5 = 3,5$ -dichloro-4-pyridyl, and $X = O$).

Melting point: 142-143°C

1H -NMR(CDC ℓ_3) δ : 3.97(3H, s), 4.41(2H, t, $J=5.0$ Hz), 4.48(2H, t, $J=5.0$ Hz), 6.17-6.22(1H, m), 6.58(1H, d, $J=10.0$ Hz), 7.26(1H, s), 7.32-7.40(1H, m), 7.45(1H, dd, $J=2.0$, 7.0Hz), 8.10(1H, s), 8.22(1H, s), 8.60(2H, s).

Example 45

[0171] The procedure of Example 39 was repeated through use of (Z)-3-(3,5-dichloro-4-pyridyl)-2-(4-hydroxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein $R^1 = H$, $R^2 = CH_3$, $R^3 = CN$, $R^4 = H$, $R^5 = 3,5$ -dichloro-4-pyridyl, and $X = O$) and 3-pyridinepropanol, to thereby obtain the compound shown below.

[0172] (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-4-(3-(3-pyridyl)propyloxy)-2-pyridyl]propenenitrile (formula (1), wherein $R^1 = 3$ -(3-pyridyl)propyl, $R^2 = CH_3$, $R^3 = CN$, $R^4 = H$, $R^5 = 3,5$ -dichloro-4-pyridyl, and $X = O$).

Melting point: 91-93°C

1H -NMR(DMSO- d_6) δ : 2.12(2H, m), 2.79(2H, t, $J=6.5$ Hz), 3.95(3H, s), 4.21 (2H, t, $J=6.5$ Hz), 7.30(1H, m), 7.56(1H, s), 7.67(1H, m), 8.28(1H, s), 8.33(1H, s), 8.47(2H, m), 8.82(2H, s).

Example 46

[0173] The procedure of Example 39 was repeated through use of (Z)-3-(3,5-dichloro-4-pyridyl)-2-(4-hydroxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein $R^1 = H$, $R^2 = CH_3$, $R^3 = CN$, $R^4 = H$, $R^5 = 3,5$ -dichloro-4-pyridyl, and $X = O$) and 4-pyridinepropanol, to thereby obtain the compound shown below.

[0174] (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-4-(3-(4-pyridyl)propyloxy)-2-pyridyl]propenenitrile (formula (1), wherein $R^1 = 3$ -(4-pyridyl)propyl, $R^2 = CH_3$, $R^3 = CN$, $R^4 = H$, $R^5 = 3,5$ -dichloro-4-pyridyl, and $X = O$).

Melting point: 124-125°C

1H -NMR(CDC ℓ_3) δ : 2.25(2H, m), 2.87(2H, m), 4.01(3H, s), 4.16(2H, t, $J=6.0$ Hz), 7.17(2H, d, $J=6.0$ Hz), 7.22(1H, s), 8.19(1H, s), 8.23(1H, s), 8.50(2H, d, $J=6.0$ Hz), 8.61(2H, s).

Example 47

[0175] The procedure of Example 39 was repeated through use of (Z)-3-(3,5-dichloro-4-pyridyl)-2-(4-hydroxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein $R^1 = H$, $R^2 = CH_3$, $R^3 = CN$, $R^4 = H$, $R^5 = 3,5$ -dichloro-4-pyridyl, and $X = O$) and N-hydroxyethylmorpholine, to thereby obtain the compound shown below.

[0176] (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-4-(2-(N-morpholino)ethoxy)-2-pyridyl]propenenitrile (formula (1), wherein $R^1 = 2$ -(N-morpholino) ethyl, $R^2 = CH_3$, $R^3 = CN$, $R^4 = H$, $R^5 = 3,5$ -dichloro-4-pyridyl, and $X = O$).

Melting point: 130-131°C
¹H-NMR(CDCℓ₃) δ : 2.50-2.70(4H, m), 2.89(2H, t, J=6.0Hz), 3.60-3.82(4H, m), 4.00(3H, s), 4.28(2H, t, J=6, 0Hz), 7.29(1H, s), 8.19(1H, s), 8.22(1H, s), 8.61 (2H, s).

5 Example 48

[0177] The procedure of Example 39 was repeated through use of (Z)-3-(3,5-dichloro-4-pyridyl)-2-(4-hydroxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein R¹ = H, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O) and 1,3-bis(BOC-amino)-2-propanol, to thereby obtain the compound shown below.

10 **[0178]** (Z)-2-[4-(1,3-bis(BOC-amino)-2-propyloxy)-5-methoxy-2-pyridyl]-3-(3,5-dichloro-4-pyridyl)propenenitrile (formula (1), wherein R¹ = 1,3-bis(BOC-amino)-2-propyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O).

Melting point: 181-181.5°C

15 ¹H-NMR(CDCℓ₃) δ : 1.43(18H, s), 3.23(2H, m), 3.66(2H, m), 3.99(3H, s), 4.54(1H, m), 5.21 (2H, m), 7.93(1H, s), 8.16(1H, s), 8.25 (1H, s), 8.60(2H, s).

Example 49

20 **[0179]** The procedure of Example 39 was repeated through use of (Z)-3-(3,5-dichloro-4-pyridyl)-2-(4-hydroxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein R¹ = H, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O) and cis-1,3-cyclopentanediol monoTBS-ether, to thereby obtain the compound shown below.

[0180] (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-4-(cis-3-(TBS-oxy)cyclopentyloxy-2-pyridyl)]propenenitrile (formula (1), wherein R¹ = cis-3-(TBS-oxy)cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O).

25 ¹H-NMR(CDCℓ₃) δ : 0.05(6H, s), 0.88(9H, s), 1.60-2.62(6H, m), 3.98(3H, s), 4.20-4.40(1H, m), 4.75-5.00(1H, m), 7.19(1H, s), 8.19(2H, s), 8.61(2H, s).

Example 50

30 **[0181]** The procedure of Example 39 was repeated through use of (Z)-3-(3,5-dichloro-4-pyridyl)-2-(4-hydroxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein R¹ = H, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O) and trans-1,3-cyclopentanediol monoTBS-ether, to thereby obtain the compound shown below.

35 **[0182]** (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-4-(trans-3-(TBS-oxy)cyclopentyloxy-2-pyridyl)]propenenitrile (formula (1), wherein R¹ = trans-3-(TBS-oxy)cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O).

¹H-NMR(CDCℓ₃) δ : 0.06(6H, s), 0.89(9H, s), 1.50-2.50(6H, m), 3.98(3H, s), 4.30-4.60(1H, m), 4.95-5.22(1H, m), 7.23(1H, s), 8.17(1H, s), 8.20(1H, s), 8.61 (2H, s).

40 Example 51

Synthesis of (Z)-2-(3-carboxyphenyl)-3-[4-(2-indanyloxy)-5-methoxy-2-pyridyl]propenenitrile (formula (1), wherein R¹ = 2-indanyl, R² = CH₃, R³ = H, R⁴ = CN, R⁵ = 3-carboxyphenyl, and X = O):

45 **[0183]** In 4 ml of dioxane, was dissolved (Z)-3-[4-(2-indanyloxy)-5-methoxy-2-pyridyl]-2-(3-methoxycarbonylphenyl)propenenitrile (formula (1), wherein R¹ = 2-indanyl, R² = CH₃, R³ = H, R⁴ = CN, R⁵ = 3-methoxycarbonylphenyl, and X = O) (426 mg, 1 mmol). To the solution was added 1N aqueous NaOH solution (1.2 ml). The mixture was stirred for 0.5 hours at room temperature. The reaction mixture was poured into 5% aqueous ammonium chloride solution. Precipitated crystals were collected by filtration, washed with water, and recrystallized from ethanol, to thereby obtain the title compound (353 mg, yield 86%).

50

Melting point: 281.5-282.5°C

¹H-NMR(DMSO-d₆) δ : 2.90-3.65(4H, m), 3.89(3H, s), 5.20-5.42(1H, m), 7.05-7.40(4H, m), 7.50-7.75(2H, m), 7.90-8.10(3H, m), 8.37(2H, s).

55

Example 52

[0184] The procedure of Example 51 was repeated through use of (Z)-2-[4-(2-indanyloxy)-5-methoxy-2-pyridyl]-

3-(2-methoxycarbonyl-4-pyridyl)propenenitrile (formula (1), wherein $R^1 = 2\text{-indanyl}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 2\text{-methoxycarbonyl-4-pyridyl}$, and $X = \text{O}$), to thereby obtain the compound shown below.

[0185] (Z)-3-(2-Carboxy-4-pyridyl)-2-[4-(2-indanyloxy)-5-methoxy-2-pyridyl]propenenitrile (formula (1), wherein $R^1 = 2\text{-indanyl}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 2\text{-carboxy-4-pyridyl}$, and $X = \text{O}$).

Melting point: 224-225°C

$^1\text{H-NMR}(\text{DMSO-}d_6) \delta$: 3.08-3.56(4H, m), 3.85(3H, s), 5.50(1H, br), 7.18-7.30(4H, m), 7.66(1H, s), 8.09-8.10(1H, m), 8.29(1H, s), 8.39(1H, s), 8.53(1H, s), 8.89(1H, d, $J=5.3\text{Hz}$).

Example 53

[0186] The procedure of Example 51 was repeated through use of (Z)-3-(4-cyclopentyloxy-5-methoxy-2-pyridyl)-2-(3-methoxycarbonylphenyl)propenenitrile (formula (1), wherein $R^1 = \text{cyclopentyl}$, $R^2 = \text{CH}_3$, $R^3 = \text{H}$, $R^4 = \text{CN}$, $R^5 = 3\text{-methoxycarbonylphenyl}$, and $X = \text{O}$), to thereby obtain the compound shown below.

[0187] (Z)-2-(3-Carboxyphenyl)-3-(4-cyclopentyloxy-5-methoxy-2-pyridyl)propenenitrile (formula (1), wherein $R^1 = \text{cyclopentyl}$, $R^2 = \text{CH}_3$, $R^3 = \text{H}$, $R^4 = \text{CN}$, $R^5 = 3\text{-carboxyphenyl}$, and $X = \text{O}$).

Melting point: 264-266°C

$^1\text{H-NMR}(\text{DMSO-}d_6) \delta$: 1.58-1.82(6H, m), 1.97-2.10(2H, m), 3.94(3H, s), 4.88-4.94(1H, m), 7.54(1H, s), 7.63(1H, t, $J=8.0\text{Hz}$), 7.96-8.03(3H, m), 8.33(1H, s), 8.35(1H, s).

Example 54

Synthesis of (Z)-2-[4-(1,3-diamino-2-propyloxy)-5-methoxy-2-pyridyl]-3-(3,5-dichloro-4-pyridyl)propenenitrile trihydrochloride (formula (1), wherein $R^1 = 1,3\text{-diamino-2-propyl}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$):

[0188] In 4 ml of ether, was dissolved (Z)-2-[4-(1,3-bis(BOC-amino)-2-propyloxy)-5-methoxy-2-pyridyl]-3-(3,5-dichloro-4-pyridyl)propenenitrile (formula (1), wherein $R^1 = 1,3\text{-bis(BOC-amino)-2-propyl}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$) (594 mg, 1 mmol). To the solution was added 4N HCl-dioxane solution (2 ml). The mixture was stirred for three hours at room temperature. Precipitated crystals were collected by filtration, washed with ether, and recrystallized from ethanol, to thereby obtain the title compound (450 mg, yield 89%).

Melting point: 174-177°C

$^1\text{H-NMR}(\text{DMSO-}d_6) \delta$: 3.23(2H, m), 3.40(2H, m), 3.97(3H, s), 5.32(1H, m), 8.22(1H, s), 8.41(1H, s), 8.72(1H, s), 8.83(2H, s).

Example 55

Synthesis of (Z)-3-(3,5-dichloro-4-pyridyl)-2-[4-(cis-(3-hydroxy)cyclopentyloxy)-5-methoxy-2-pyridyl]propenenitrile (formula (1), wherein $R^1 = \text{cis-(3-hydroxy)cyclopentyl}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$):

[0189] In 2 ml of THF, was dissolved (Z)-3-(3,5-dichloro-4-pyridyl)-2-[5-methoxy-4-(cis-3-(TBS-oxy)cyclopentyloxy)-2-pyridyl]propenenitrile (formula (1), wherein $R^1 = \text{cis-3-(TBS-oxy)cyclopentyl}$, $R^2 = \text{CH}_3$, $R^3 = \text{CN}$, $R^4 = \text{H}$, $R^5 = 3,5\text{-dichloro-4-pyridyl}$, and $X = \text{O}$) (520 mg, 1 mmol). To the solution was added 1M tetrabutylammonium fluoride-THF solution (2.2 ml), and the mixture was stirred for five hours at room temperature. The reaction mixture was evaporated to dryness and then water was added to the residue. The mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography and recrystallized from a benzene-hexane, to thereby obtain the title compound (240 mg, yield 59%).

Melting point: 134-135°C

$^1\text{H-NMR}(\text{CDCl}_3) \delta$: 1.90-2.24(6H, m), 2.39(1H, d, $J=8.0\text{Hz}$), 3.98(3H, s), 4.38-4.50(1H, m), 5.04-5.08(1H, m), 7.26(1H, s), 8.20(1H, s), 8.22(1H, s), 8.61(2H, s).

Example 56

[0190] The procedure of Example 55 was repeated through use of (Z)-3-(3,5-dichloro-4-pyridyl)-2-[5-methoxy-4-(trans-3-(TBS-oxy)cyclopentyloxy)-2-pyridyl]propenenitrile (formula (1), wherein R¹ = trans-3-(TBS-oxy)cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O), to thereby obtain the compound shown below.

[0191] (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[4-(trans-(3-hydroxy)cyclopentyloxy)-5-methoxy-2-pyridyl]propenenitrile (formula (1), wherein R¹ = trans-(3-hydroxy)cyclopentyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 3,5-dichloro-4-pyridyl, and X = O).

Melting point: 136-137°C

¹H-NMR(CDCl₃) δ : 1.58(1H, br), 1.70-1.80(1H, m), 1.90-2.00(1H, m), 2.07-2.28(3H, m), 2.35-2.46(1H, m), 3.98(3H, s), 4.58-4.62(1H, m), 5.04-5.07(1H, m), 7.24(1H, s), 8.17(1H, s), 8.20(1H, s), 8.61(2H, s).

Example 57

[0192] The procedure of Example 1 was repeated through use of 5-cyclopentyloxy-6-methoxy-3-pyridineacetonitrile (Preparation Example 16) and 3,5-dichloro-4-pyridinecarbaldehyde (Preparation Example 7), to thereby obtain the compound shown below.

[0193] (Z)-2-(5-Cyclopentyloxy-6-methoxy-3-pyridyl)-3-(3,5-dichloro-4-pyridyl)propenenitrile.

Melting point: 143-144°C

¹H-NMR(CDCl₃) δ : 1.60-2.05 (8H, m), 4.05(3H, s), 4.86(1H, m), 7.25(1H, d, J=2.0Hz), 7.27(1H, s), 8.11 (1H, d, J=2.0Hz), 8.62(2H, s).

Example 58

[0194] The procedure of Example 1 was repeated through use of 6-cyclopentyloxy-5-methoxy-2-pyridineacetonitrile (Preparation Example 17) and 3,5-dichloro-4-pyridinecarbaldehyde (Preparation Example 7), to thereby obtain the compound shown below.

[0195] (Z)-2-(6-Cyclopentyloxy-5-methoxy-2-pyridyl)-3-(3,5-dichloro-4-pyridyl)propenenitrile.

Melting point: 137-138°C

¹H-NMR(CDCl₃) δ : 1.61-2.12(8H, m), 3.91(3H, s), 5.50(1H, m), 7.06(1H, d, J=8.0Hz), 7.31 (1H, d, J=8.0Hz), 8.07 (1H, s), 8.60 (2H, s).

Example 59

[0196] The procedure of Example 1 was repeated through use of 5-methoxy-4-[2-(4-methyl-5-thiazolyl)ethyloxy]-2-pyridineacetonitrile (Preparation Example 18) and methyl 4-formyl-2-picolinate, to thereby obtain the compound shown below.

[0197] (Z)-2-[5-methoxy-4-(2-(4-methyl-5-thiazolyl)ethyloxy)-2-pyridyl]-3-(2-methoxycarbonyl-4-pyridyl)propenenitrile (formula (1), wherein R¹ = 2-(4-methyl-5-thiazolyl)ethyl, R² = CH₃, R³ = CN, R⁴ = H, R⁵ = 2-methoxycarbonyl-4-pyridyl, and X = O).

Melting point: 161-162°C

¹H-NMR(CDCl₃) δ : 2.49(3H, s), 3.37(2H, t, J=6.5Hz), 4.01(3H, s), 4.05(3H, s), 4.32(2H, t, J=6.5Hz), 7.25(1H, s), 8.04(1H, dd, J=1.0, 5.5Hz), 8.20(1H, s), 8.34(1H, s), 8.47(1H, d, J=1.0Hz), 8.63(1H, s), 8.89 (1H, d, J=5.5Hz).

[0198] Similarly, the following compounds can also be prepared.

(Z)-2-(6-Cyclopentyloxy-5-methoxy-2-pyridyl)-3-(2,6-dichlorophenyl)propenenitrile

(Z)-2-(6-Cyclopentyloxy-5-methoxy-2-pyridyl)-3-(3-pyridyl)propenenitrile

(Z)-2-(6-Cyclopentyloxy-5-methoxy-2-pyridyl)-3-(4-pyridyl)propenenitrile

(Z)-3-(3,5-Dichloro-4-pyridyl)-2-(5-methoxy-6-phenethyloxy-2-pyridyl)propenenitrile

(Z)-3-(3,5-Dichloro-4-pyridyl)-2-(5-methoxy-6-(3-phenylpropyloxy)-2-pyridyl)propenenitrile

(Z)-2-(6-Butyloxy-5-methoxy-2-pyridyl)-3-(3,5-dichloro-4-pyridyl)propenenitrile

(Z)-3-(3,5-Dichloro-4-pyridyl)-2-[6-(1-ethylpropyloxy)-5-methoxy-2-pyridyl]propenenitrile

(Z)-3-(3,5-Dichloro-4-pyridyl)-2-[6-(2-indanyloxy)-5-methoxy-2-pyridyl]propenenitrile

- (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-6-(tetrahydro-3-furanyloxy)-2-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-6-(exo-2-norbornyloxy)-2-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-(5-methoxy-6-methoxymethyloxy-2-pyridyl)propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-(6-hydroxy-5-methoxypyridyl)propenenitrile
 5 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[6-(3-hydroxypropyloxy)-5-methoxy-2-pyridyl]propenenitrile
 (Z)-3-(6-Cyclopentyloxy-5-methoxy-2-pyridyl)-2-(3,5-dichloro-4-pyridyl)propenenitrile
 (Z)-2-[6-Cyclopentyloxy-5-methoxy-2-pyridyl]-3-(3-fluoro-4-pyridyl)propenenitrile
 (Z)-2-[6-(2-Indanyloxy)-5-methoxy-2-pyridyl]-3-(2-methoxycarbonyl-4-pyridyl)propenenitrile
 (Z)-2-[6-(2-Indanyloxy)-5-methoxy-2-pyridyl]-3-(4-pyridyl)propenenitrile
 10 4-[(Z)-2-Cyano-2-(6-(2-indanyloxy)-5-methoxy-2-pyridyl)-1-ethenyl]pyridine N-oxide
 4-[(Z)-2-Cyano-2-(6-(2-indanyloxy)-5-methoxy-2-pyridyl)-1-ethenyl]-3,5-dichloropyridine N-oxide
 (Z)-3-(3-Carboxyphenyl)-2-(6-cyclopentyloxy-5-methoxy-2-pyridyl)propenenitrile
 (Z)-3-(6-Cyclopentyloxy-5-methoxy-2-pyridyl)-2-(3-methoxycarbonylphenyl)propenenitrile
 (Z)-3-[6-(2-Indanyloxy)-5-methoxy-2-pyridyl]-2-(3-methoxycarbonylphenyl)propenenitrile
 15 (Z)-3-[6-(2-Indanyloxy)-5-methoxy-2-pyridyl]-2-(4-pyridyl)propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[6-(2-hydroxyethyloxy)-5-methoxy-2-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[6-(4-hydroxybutyloxy)-5-methoxy-2-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[6-(5-hydroxypentyloxy)-5-methoxy-2-pyridyl]propenenitrile
 (Z)-2-(6-Cyclopropylmethyloxy-5-methoxy-2-pyridyl)-3-(3,5-dichloro-4-pyridyl)propenenitrile
 20 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-6-(2-(2-pyridyl)ethyloxy)-2-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-6-(2-(4-methyl-5-thiazolyl)ethyloxy)-2-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-6-(2-(2-pyridone-1-yl)ethyloxy)-2-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-6-(3-(3-pyridyl)propyloxy)-2-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-6-(3-(4-pyridyl)propyloxy)-2-pyridyl]propenenitrile
 25 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-6-(2-(N-morpholino)ethyloxy)-2-pyridyl]propenenitrile
 (Z)-2-(3-Carboxyphenyl)-3-[6-(2-indanyloxy)-5-methoxy-2-pyridyl]propenenitrile
 (Z)-3-(2-Carboxy-4-pyridyl)-2-[6-(2-indanyloxy)-5-methoxy-2-pyridyl]propenenitrile
 (Z)-2-(3-Carboxyphenyl)-3-(6-cyclopentyloxy-5-methoxy-2-pyridyl)propenenitrile
 (Z)-2-[5-Methoxy-6-(2-(4-methyl-5-thiazolyl)ethyloxy)-2-pyridyl]-3-(2-methoxycarbonyl-4-pyridyl)propenenitrile
 30 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-6-(cis-3-(TBS-oxy)cyclopentyloxy)-2-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-methoxy-6-(trans-3-(TBS-oxy)cyclopentyloxy)-2-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[6-(cis-(3-hydroxy) cyclopentyloxy)-5-methoxy-2-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[6-(trans-(3-hydroxy) cyclopentyloxy)-5-methoxy-2-pyridyl]propenenitrile
 (Z)-2-(5-Cyclopentyloxy-6-methoxy-3-pyridyl)-3-(2,6-dichlorophenyl)propenenitrile
 35 (Z)-2-(5-Cyclopentyloxy-6-methoxy-3-pyridyl)-3-(3-pyridyl)propenenitrile
 (Z)-2-(5-Cyclopentyloxy-6-methoxy-3-pyridyl)-3-(4-pyridyl)propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-(6-methoxy-5-phenethyloxy-3-pyridyl)propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[6-methoxy-5-(3-phenylpropyloxy)-3-pyridyl]propenenitrile
 (Z)-2-(5-Butyloxy-6-methoxy-3-pyridyl)-3-(3,5-dichloro-4-pyridyl)propenenitrile
 40 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-(1-ethylpropyloxy)-6-methoxy-3-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-(2-indanyloxy)-6-methoxy-3-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[6-methoxy-5-(tetrahydro-3-furanyloxy)-3-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[6-methoxy-5-(exo-2-norbornyloxy)-3-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-9-pyridyl)-2-(6-methoxy-5-methoxymethyloxy-3-pyridyl)propenenitrile
 45 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-(5-hydroxy-6-methoxy-3-pyridyl)propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-(3-hydroxypropyloxy)-6-methoxy-3-pyridyl]propenenitrile
 (Z)-3-(5-Cyclopentyloxy-6-methoxy-3-pyridyl)-2-(3,5-dichloro-4-pyridyl)propenenitrile
 (Z)-2-(5-Cyclopentyloxy-6-methoxy-3-pyridyl)-3-(3-fluoro-4-pyridyl)propenenitrile
 (Z)-2-[5-(2-Indanyloxy)-6-methoxy-3-pyridyl]-3-(2-methoxycarbonyl-4-pyridyl)propenenitrile
 50 (Z)-2-[5-(2-Indanyloxy)-6-methoxy-3-pyridyl]-3-(4-pyridyl)propenenitrile
 4-[(Z)-2-Cyano-2-(5-(2-indanyloxy)-6-methoxy-3-pyridyl)-1-ethenyl]pyridine N-oxide
 4-[(Z)-2-Cyano-2-(5-(2-indanyloxy)-6-methoxy-3-pyridyl)-1-ethenyl]-3,5-dichloropyridine N-oxide
 (Z)-3-(3-Carboxyphenyl)-2-[5-cyclopentyloxy-6-methoxy-3-pyridyl]propenenitrile
 (Z)-3-(5-Cyclopentyloxy-6-methoxy-3-pyridyl)-2-(3-methoxycarbonylphenyl)propenenitrile
 55 (Z)-3-[5-(2-Indanyloxy)-6-methoxy-3-pyridyl]-2-(3-methoxycarbonylphenyl)propenenitrile
 (Z)-3-[5-(2-Indanyloxy)-6-methoxy-3-pyridyl]-2-(4-pyridyl)propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-(2-hydroxyethyloxy)-6-methoxy-3-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-(4-hydroxybutyloxy)-6-methoxy-3-pyridyl]propenenitrile

(Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-(5-hydroxypentyloxy)-6-methoxy-3-pyridyl]propenenitrile
 (Z)-2-(5-Cyclopropylmethoxy-6-methoxy-3-pyridyl)-3-(3,5-dichloro-4-pyridyl)propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[6-methoxy-5-(2-(2-pyridyl)ethyloxy)-3-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[6-methoxy-5-(2-(4-methyl-5-thiazolyl)ethyloxy)-3-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[6-methoxy-5-(2-(2-pyridone-1-yl)ethyloxy)-3-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[6-methoxy-5-(3-(3-pyridyl)propyloxy)-3-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[6-methoxy-5-(3-(4-pyridyl)propyloxy)-3-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[6-methoxy-5-(2-(N-morpholino)ethyloxy)-3-pyridyl]propenenitrile
 (Z)-2-(3-Carboxyphenyl)-3-[5-(2-indanyloxy)-6-methoxy-3-pyridyl]propenenitrile
 (Z)-3-(2-Carboxy-4-pyridyl)-2-[5-(2-indanyloxy)-6-methoxy-3-pyridyl]propenenitrile
 (Z)-2-(3-Carboxyphenyl)-3-(5-cyclopentyloxy-6-methoxy-3-pyridyl)propenenitrile
 (Z)-2-[6-Methoxy-5-(2-(4-methyl-5-thiazolyl)ethyloxy)-3-pyridyl]-3-(2-methoxycarbonyl-4-pyridyl)propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[6-methoxy-5-(cis-3-(TBS-oxy)cyclopentyloxy)-3-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[6-methoxy-5-(trans-3-(TBS-oxy)cyclopentyloxy)-3-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-(cis-(3-hydroxy)cyclopentyloxy)-6-methoxy-3-pyridyl]propenenitrile
 (Z)-3-(3,5-Dichloro-4-pyridyl)-2-[5-(trans-(3-hydroxy)cyclopentyloxy)-6-methoxy-3-pyridyl]propenenitrile

Test Example 1 PDE Inhibitory Activity Test

[0199] A variety of PDE isozymes shown below were isolated from human tissue and purified in accordance with the method described in literature.

PDE III Human platelet

H. Hidaka, *et al.*, *Bioph. Bioch. Acta*, (1976), 429, p485

P. Grant, *et al.*, *Biochemistry*, (1984), 23, p1801

PDE IV Human histocytic lymphoma (U-937)

T. Torphy, *et al.*, *J. Pharm. Exp. Ther.*, (1992), 263, p1195

M. DiSanto, *et al.*, *BBRC*, (1993), 197, p1126

PDE V Human platelet

H. Hidaka, *et al.*, *Bioph. Bioch. Acta*, (1976), 429, p485

P. Grant, *et al.*, *Biochemistry*, (1984), 23, p1801

C.D. Nicholson, *et al.*, *Trends Pharmacol. Sci.*, (1991), 12, p19.

[0200] The PDE activity was determined through use of a modified two-step assay method described by Hidaka *et al.* (*Bioph. Bioch. Acta.*, (1976), 429, p485).

[0201] Briefly, [³H]cAMP and [³H]cGMP are hydrolyzed by their respective PDE isozymes to form [³H]5'-AMP and [³H]5'-GMP, respectively. Subsequently, [³H]5'-AMP and [³H]5'-GMP are transformed into [³H]adenosine and [³H]guanosine, respectively, due to the action of nucleotidases. Unreacted [³H]cAMP and [³H]cGMP are removed, causing them to bond to ion exchange resin, and the quantity of eluted [³H]adenosine or [³H]guanosine was counted in a liquid scintillation counter.

[0202] The diluted enzyme solution contains 50 mM Tris-HCl (pH 8.0), 5 mM MgCl₂, and 50 µg of bovine serum albumin, wherein the concentrations represent final concentrations. The substrate concentration is 1 µM. The concentration of each test compound varies between 0.1 nM and 100 µM. Each test sample is incubated for 20 minutes at 30°C, and the PDE reaction is terminated by boiling for 2 minutes. The nucleotidase reaction was induced by adding snake venom nucleotidase to the above-described reaction mixture and incubating the resultant mixture for 20 minutes at 30°C.

[0203] The IC₅₀ values of the test compounds were obtained from concentration-reaction curves within the concentration range of 0.1 nM to 100 µM.

Table 1

PDE inhibitory Activity			
Compound	PDE III IC ₅₀ (µM)	PDE IV IC ₅₀ (µM)	PDE V IC ₅₀ (µM)
Example 1	10	0.0026	>100
Example 14	>100	0.0059	5.6
Example 15	91	0.0048	56

Table 1 (continued)

PDE inhibitory Activity			
Compound	PDE III IC ₅₀ (μM)	PDE IV IC ₅₀ (μM)	PDE V IC ₅₀ (μM)
Example 16	15	0.015	31
Example 17	>100	0.036	>100
Example 18	18	0.036	12
Example 19	>100	0.00065	>100
Example 20	56	0.011	>100
Rolipram	>100	5.0	>100

Test Example 2 TNF-α Production Inhibition Test

[0204] Human promonocytic leukemia cells (U 937 cells, 1 x 10⁵ cells/400 μl) were inoculated on a 24-well culture plate. By use of an RPMI 1640 culture liquid (supplemented with 10% FCS) containing 50 nM PMA, the cells were incubated for 72 hours, to thereby induce differentiation into monocyte/macrophage (see Sarkiz Daniel-Issakani, Allem M. Spiegel and Berta Strulovici (1989), *J. Biol. Chem.* 264, p20240-20247). Subsequently, the culture supernatant was discarded, and an RPMI 1640 culture liquid (supplemented with 10% FCS) containing 10 ng/ml of LPS (lipopolysaccharide; E. coli, 0111:B4) was added. Each compound was added one hour before the LPS treatment, so as to achieve concentrations of 100 μM, 10 μM, 1 μM, and 0.1 μM. Six hours after addition of LPS, the quantity of produced TNF-α in the supernatant was measured by use of a human TNF-α ELISA kit (Amersham, code RPN 2758). For respective doses of each compound, %control was calculated, wherein the quantity of TNF-α produced when LPS treatment was performed and the compound was not added was considered 100%. Further, based on primary regression curves, there were calculated IC₅₀ values in terms of TNF-α production inhibitory activity for respective compounds.

Table 2

TNF-α Production Inhibition	
Compound	IC ₅₀ (μM)
Example 1	10.2
Example 4	7.6
Example 10	10
Example 11	5.5
Example 16	13.1
Example 19	2.9
Example 20	7.1
Example 21	13.3
Rolipram	100

Preparation Example 1 Tablet	
Compound of Example 1	50 mg
Crystalline cellulose	50 mg
Lactose	50 mg
Hydroxypropylcellulose	18 mg
Magnesium stearate	2 mg
Total	170 mg

[0205] Tablets each having the above composition were prepared through a customary method. If necessary, these

EP 0 882 714 B1

tablets may be processed into sugar-coated tablets or film-coated tablets.

Preparation Example 2 Capsule	
Compound of Example 1	50 mg
Light silicic acid anhydride	25 mg
Lactose	100 mg
Starch	50 mg
Talc	25 mg

Total	250 mg

[0206] The above ingredients were filled in a No.1 capsule, to thereby prepare capsule preparations.

Preparation Example 3 Granules	
Compound of Example 1	50 mg
Lactose	600 mg
Cornstarch	200 mg
Carboxymethylcellulose-Na	20 mg
Hydroxypropylcellulose	130 mg
Total	1000 mg

[0207] Granules of the above composition were prepared using a customary method.

Preparation Example 4 Powder	
Compound of Example 1	50 mg
Light silicic acid anhydride	20 mg
Precipitated calcium carbonate	10 mg
Lactose	250 mg
Starch	70 mg

Total	400 mg

[0208] A powder product having the above composition was prepared using a customary method.

Preparation Example 5 Injection	
Compound of Example 19	5 mg
Hydrogenated castor oil	85 mg
Propylene glycol	60 mg
Glucose	50 mg
Distilled water for injection	Suitable amount

Total	1 ml in total

[0209] An injection having the above composition was prepared through a customary method.

Preparation Example 6 Intravenous drip infusion	
Compound of Example 19	50 mg
Glucose	5 g
Na ₂ HPO ₄ anhydrate	10 mg
Citric acid	14.5 mg
Distilled water for injection	Suitable amount

Total	100 ml in total


[0210] An intravenous drip infusion was prepared through a customary method.

INDUSTRIAL APPLICABILITY

[0211] The substituted vinylpyridine derivative of the present invention is endowed with strong and selective PDE IV inhibitory activity, and strong TNF- α production inhibitory activity. Thus, drugs designed on the basis of the selective PDE IV inhibitory activity are useful for the prevention and treatment of various diseases, including immediate or delayed asthma; allergies such as airway-hypersensitive allergy and other allergies stemming from the inhibition of activation of inflammatory blood cells such as eosinocytes; autoimmune diseases such as atopy and rheumatism; depression associated with disturbed metabolism of the cerebrum; cerebral infarction; senile dementia; and memory disorders associated with Parkinson's disease. Also, drugs designed on the basis of the TNF- α production inhibitory activity are useful for the prevention and treatment of various diseases, including rheumatism, osteoporosis, type I and type II diabetes, cancers, infections with HIV, AIDS, and shock caused by intracellular toxins. Moreover, since the compounds of the present invention have both selective PDE IV inhibitory action and TNF- α production inhibitory action, they are useful for the prevention and treatment of a wide variety of inflammatory diseases and autoimmune diseases.

Claims

1. A substituted vinylpyridine derivative represented by the following formula (1):



wherein

R¹ represents

a hydrogen atom,
a linear, branched, cyclic, cyclic-linear, or cyclic branched alkyl group,
a linear, branched, or cyclic alkenyl group,
a hydroxyalkyl group which may have
a substituent selected from one or more hydroxy groups which may be substituted with

an alkoxycarbonyl group,
an acyl group, or
a TBS (t-butyldimethyl-silyl)group,

an alkoxyalkyl group,
an alkoxycarbonyl alkyl group,
an alkoxyalkoxyalkyl group,
an aminoalkyl group which may have
a substituent selected from

an alkoxycarbonyl group or
an acyl group,

a saturated heterocyclic group which may have
a substituent selected from 1-3 group(s) selected from

- hydroxy,
halogeno,
C1-6 alkyl,
C1-6 alkoxy,
C1-6 halogenoalkyl,
cyano, and
nitro,
- an aralkyl group which may have
a substituent selected from one or more of
- methoxy group(s),
alkoxycarbonyl group(s), or
alkylenedioxy group(s)
- at o-, m-, and/or p-position,
a benzocycloalkyl group which may have
a substituent selected from 1-3 group (s) selected from
- hydroxy,
halogeno,
C1-6 alkyl,
C1-6 alkoxy,
C1-6 halogenoalkyl,
cyano, and
nitro, or
- an alkyl group having a heterocyclic group which may have
a substituent selected from 1-3 group(s) selected from
- hydroxy,
halogeno,
C1-6 alkyl,
C1-6 alkoxy,
C1-6 halogenoalkyl,
cyano, and
nitro;
- R² represents an alkyl group;
R³ represents
- a nitrile group,
a carboxyl group, or
an alkoxycarbonyl group and
- R⁴ represents a hydrogen atom;
R⁵ represents
- a monocyclic or ring-condensed aryl group which may have
1-3 substituent(s) selected from
- halogeno,
C1-6 alkyl,
C1-6 alkoxy,
C1-6 halogenoalkyl,
C1-6 alkoxycarbonyl,
carboxyl,
cyano, and

nitro

or

a monocyclic or ring-condensed heteroaryl group which may have
1-3 substituent(s) selected from

halogeno,
C1-6 alkyl,
C1-6 alkoxy,
C1-6 halogenoalkyl,
C1-6 alkoxy carbonyl,
carboxyl,
cyano, and
nitro;

X represents


an oxygen atom or
a sulfur atom; and

one of Q¹, Q², and Q³ represents a nitrogen atom and the other two represent CH;
as well as a salt thereof, a hydrate thereof, or an N-oxide thereof.

2. A drug containing as the active ingredient a substituted vinylpyridine derivative as described in Claim 1, a salt thereof, a hydrate thereof, or an N-oxide thereof.
3. The drug according to Claim 2, which is a phosphodiesterase IV inhibitor.
4. The drug according to Claim 2, which is a tumor necrotizing factor- α production inhibitory agent.
5. The drug according to Claim 2, which is a preventive or therapeutic agent for diseases based on phosphodiesterase IV and/or tumor necrotizing factor- α .
6. A pharmaceutical composition containing a substituted vinylpyridine derivative as described in Claim 1, a salt thereof, a hydrate thereof, or an N-oxide thereof, and a pharmaceutically acceptable carrier.
7. Use of a substituted vinylpyridine derivative as described in Claim 1, a salt thereof, a hydrate thereof, or an N-oxide thereof for the manufacture of a medicament.
8. Use according to Claim 7, whereby the medicament is for the prevention and treatment of a disease caused by the enhancement of phosphodiesterase IV activity.
9. Use according to claim 7, whereby the medicament is for the prevention and treatment of a disease caused by the production of tumor necrotizing factor- α .
10. Use according to any one of claims 7 to 9, whereby the medicament is for the prevention and treatment of immediate or delayed asthma; allergies such as airway-hypersensitive allergy and other allergies stemming from the inhibition of activation of inflammatory blood cells such as eosinocytes; autoimmune diseases such as atopy and rheumatism; depression associated with disturbed metabolism of the cerebrum; cerebral infarction; senile dementia; memory disorders associated with Parkinson's disease; rheumatism, osteoporosis, type I and type II diabetes, cancers, infections with HIV, AIDS, shock caused by intracellular toxins; and inflammatory diseases and autoimmune diseases.

Patentansprüche

1. Substituiertes Vinylpyridin-Derivat, das durch die folgende Formel (1) dargestellt wird:



wobei

R¹ für

15 ein Wasserstoffatom,
eine lineare, verzweigte, cyclische, cyclisch-lineare oder cyclisch verzweigte Alkylgruppe,
eine lineare, verzweigte oder cyclische Alkenylgruppe,
eine Hydroxyalkylgruppe, die
20 einen Substituenten aufweisen kann, der ausgewählt ist aus
einer oder mehreren Hydroxygruppe(n), die substituiert sein kann oder können durch

eine Alkoxy-carbonylgruppe,
eine Acylgruppe oder
25 eine TBS (tert.-Butyldimethylsilyl)-Gruppe,

eine Alkoxyalkylgruppe,
eine Alkoxy-carbonylalkylgruppe,
eine Alkoxyalkoxyalkylgruppe,
30 eine Aminoalkylgruppe, die
einen Substituenten aufweisen kann, der ausgewählt ist aus

einer Alkoxy-carbonylgruppe oder
einer Acylgruppe,

35 eine gesättigte heterocyclische Gruppe, die
einen Substituenten aufweisen kann, der ausgewählt ist aus 1-3 Gruppe(n), die ausgewählt ist
oder sind aus

40 Hydroxy,
Halogen,
C1-6 Alkyl,
C1-6 Alkoxy,
C1-6 Halogenalkyl,
45 Cyano und
Nitro,

eine A-alkylgruppe, die
einen Substituenten aufweisen kann, der ausgewählt ist aus
50 einer oder mehreren

Methoxygruppe(n),
Alkoxy-carbonylgruppe(n) oder
Alkylendioxygruppe(n)

55 an einer o-, m-, und/oder p-Position,
eine Benzocycloalkylgruppe, die
einen Substituenten aufweisen kann, der ausgewählt ist aus 1-3 Gruppe(n), der oder die ausge-

wählt ist oder sind aus

Hydroxy,
Halogen,
C1-6 Alkyl,
C1-6 Alkoxy,
C1-6 Halogenalkyl,
Cyano und
Nitro, oder

eine eine heterocyclische Gruppe aufweisende Alkylgruppe steht, die
einen Substituenten aufweisen kann, der ausgewählt ist aus 1-3 Gruppe(n), der oder die ausge-
wählt ist oder sind aus

Hydroxy,
Halogen,
C1-6 Alkyl,
C1-6 Alkoxy,
C1-6 Halogenalkyl,
Cyano und
Nitro;

R² für eine Alkylgruppe steht;
R³ für

eine Nitrilgruppe,
eine Carboxylgruppe oder
eine Alkoxy-carbonylgruppe steht; und

R⁴ für ein Wasserstoffatom steht;
R⁵ für

eine monocyclische oder ein kondensiertes Ringsystem enthaltende Arylgruppe, die
1-3 Substituenten aufweisen kann, der oder die ausgewählt ist oder sind aus

Halogen,
C1-6 Alkyl,
C1-6 Alkoxy,
C1-6 Halogenalkyl,
C1-6 Alkoxy-carbonyl,
Carboxyl,
Cyano und
Nitro

oder
eine monocyclische oder ein kondensiertes Ringsystem enthaltende Heteroarylgruppe steht, die
1-3 Substituenten aufweisen kann, der oder die ausgewählt ist oder sind aus

Halogen,
C1-6 Alkyl,
C1-6 Alkoxy,
C1-6 Halogenalkyl,
C1-6 Alkoxy-carbonyl,
Carboxyl,
Cyano und
Nitro;

X für

ein Sauerstoffatom oder
ein Schwefelatom steht; und

eines der Q¹, Q², und Q³ für ein Stickstoffatom steht und die anderen zwei für CH stehen;
sowie ein Salz davon, ein Hydrat davon oder ein N-Oxid davon.

2. Arzneimittel, das als aktiven oder wirksamen Inhaltsstoff ein substituiertes Vinylpyridin-Derivat wie es in Anspruch 1 beschrieben ist, ein Salz davon, ein Hydrat davon oder ein N-Oxid davon enthält.

3. Das Arzneimittel nach Anspruch 2, das ein Phosphodiesterase IV-Inhibitor ist.

4. Das Arzneimittel nach Anspruch 2, das ein die Produktion des Tumornekrose-Faktor α inhibierendes Mittel ist.

5. Das Arzneimittel nach Anspruch 2, das ein vorbeugendes oder therapeutisches Mittel gegen Krankheiten ist, die auf Phosphodiesterase IV und/oder den Tumornekrose-Faktor α basieren.

6. Pharmazeutische Zusammensetzung, die ein substituiertes Vinylpyridin-Derivat, wie es in Anspruch 1 beschrieben ist, ein Salz davon, ein Hydrat davon oder ein N-Oxid davon und einen pharmazeutisch verträglichen oder unbedenklichen Träger enthält.

7. Verwendung eines substituierten Vinylpyridin-Derivats, wie es in Anspruch 1 beschrieben ist, eines Salzes davon, eines Hydrats davon oder eines N-Oxids davon für die Herstellung eines Medikaments.


8. Verwendung gemäß Anspruch 7, wobei das Medikament zur Vorbeugung und Behandlung einer Krankheit dient, die verursacht wird durch die Steigerung der Phosphodiesterase IV-Aktivität.

9. Verwendung gemäß Anspruch 7, wobei das Medikament zur Vorbeugung und Behandlung einer Krankheit dient, die verursacht wird durch die Produktion des Tumornekrose-Faktors α .

10. Verwendung gemäß einem der Ansprüche 7 bis 9, wobei das Medikament zur Vorbeugung und Behandlung dient von direktem oder verzögertem Asthma; Allergien, wie zum Beispiel einer hypersensiblen Luftwegallergie und anderen Allergien, die von der Inhibierung der Aktivierung entzündlicher Blutzellen, wie zum Beispiel eosinophiler Granulozyten, herrühren; Autoimmunkrankheiten, wie zum Beispiel Atopie und Rheumatismus; Depression oder Eindrückung, die im Zusammenhang steht mit einem gestörten Metabolismus des Zerebrum oder Gehirns; zerebraler Infarzierung oder Infarktbildung; seniler Demenz; Gedächtnisstörungen, die im Zusammenhang stehen mit der Parkinson-Krankheit; Rheumatismus, Osteoporose, Diabetes vom Typ I und Typ II, Krebs, Infektionen mit HIV, AIDS, einem Schock, der verursacht wird durch intrazelluläre Toxine; und entzündliche Krankheiten und Autoimmunkrankheiten.

Revendications

1. Dérivé de vinylpyridine substituée représenté par la formule (1) suivante :



dans laquelle

R¹ représente

- un atome d'hydrogène,
 un groupe alkyle linéaire, ramifié, cyclique, cyclique linéaire ou cyclique ramifié,
 un groupe alcényle linéaire, ramifié ou cyclique,
 un groupe hydroxyalkyle qui peut avoir
- 5 un substituant constitué par
 un ou plusieurs groupe(s) hydroxy qui peut(peuvent) être substitué(s) par
- un groupe alkoxy-carbonyle,
 un groupe acyle, ou
- 10 un groupe TBS (t-butyldiméthylsilyle),
- un groupe alkoxyalkyle,
 un groupe alkoxy-carbonylealkyle,
 un groupe alkoxyalkoxyalkyle,
 un groupe aminoalkyle qui peut avoir
- 15 un substituant choisi parmi
- un groupe alkoxy-carbonyle et
 un groupe acyle,
- 20 un groupe hétérocyclique saturé qui peut avoir
 un substituant constitué par 1-3 groupe(s) choisi(s) parmi
- hydroxy,
 halogéno,
 alkyle en C1-6,
 alkoxy en C1-6,
 halogénoalkyle en C1-6,
 cyano, et
- 25 nitro,
- 30 un groupe aralkyle qui peut avoir
 un substituant constitué par un ou plusieurs
- 35 groupe(s) méthoxy,
 groupe(s) alkoxy-carbonyle, ou
 groupe(s) alkylène-dioxy
- en position o-, m-, et/ou p-,
 un groupe benzocycloalkyle qui peut avoir
- 40 un substituant constitué par 1-3 groupe(s) choisi(s) parmi
- hydroxy,
 halogéno,
 alkyle en C1-6,
 alkoxy en C1-6,
 halogénoalkyle en C1-6,
 cyano, et
- 45 nitro, ou
- 50 un groupe alkyle ayant un groupe hétérocyclique qui peut avoir
 un substituant constitué par 1-3 groupe(s) choisi(s) parmi
- hydroxy,
 halogéno,
 alkyle en C1-6,
 alkoxy en C1-6,
 halogénoalkyle en C1-6,
- 55

cyano, et
nitro ;

R² représente un groupe alkyle ;
R³ représente

un groupe nitrile,
un groupe carboxyle, ou
un groupe alkoxy-carbonyl et

R⁴ représente un atome d'hydrogène ;
R⁵ représente

un groupe aryle monocyclique ou condensé avec un cycle, lequel groupe peut avoir
1-3 substituant(s) choisi(s) parmi

halogéno,
alkyle en C1-6,
alkoxy en C1-6,
halogénoalkyle en C1-6,
alkoxy-carbonyl en C1-6,
carboxyle,
cyano, et
nitro

ou
un groupe hétéroaryle monocyclique ou condensé avec un cycle, lequel groupe peut avoir
1,3 substituant(s) choisi(s) parmi

halogéno,
alkyle en C1-6,
alkoxy en C1-6,
halogénoalkyle en C1-6,
alkoxy-carbonyl en C1-6,
carboxyle,
cyano, et
nitro ;

X représente

un atome d'oxygène ou
un atome de soufre ; et

l'un de Q¹, Q² et Q³ représente un atome d'azote et les deux autres représentent CH ;
ainsi qu'un sel de celui-ci, un hydrate de celui-ci, ou un N-oxyde de celui-ci.

2. Médicament contenant en tant qu'ingrédient actif un dérivé de vinylpyridine substituée tel que décrit dans la revendication 1, un sel de celui-ci, un hydrate de celui-ci, ou un N-oxyde de celui-ci.
3. Médicament selon la revendication 2, qui est un inhibiteur de la phosphodiesterase IV.
4. Médicament selon la revendication 2, qui est un agent d'inhibition de la production du facteur α de nécrose d'une tumeur.
5. Médicament selon la revendication 2, qui est un agent préventif ou thérapeutique pour des maladies fondées sur la phosphodiesterase IV et/ou le facteur α de nécrose d'une tumeur.
6. Composition pharmaceutique contenant un dérivé de vinylpyridine substituée tel que décrit dans la revendication

1, un sel de celui-ci, un hydrate de celui-ci, ou un N-oxyde de celui-ci, et un véhicule pharmaceutiquement acceptable.

7. Utilisation d'un dérivé de vinylpyridine substituée tel que décrit dans la revendication 1, d'un sel de celui-ci, d'un hydrate de celui-ci, ou d'un N-oxyde de celui-ci pour la fabrication d'un médicament.

8. Utilisation selon la revendication 7, le médicament étant pour la prévention et le traitement d'une maladie provoquée par l'augmentation de l'activité de la phosphodiesterase IV.

9. Utilisation selon la revendication 7, le médicament étant pour la prévention et le traitement d'une maladie provoquée par la production du facteur α de nécrose d'une tumeur.

10. Utilisation selon l'une quelconque des revendications 7 à 9, le médicament étant pour la prévention et le traitement de l'asthme immédiat ou différé ; d'allergies telles que l'allergie hypersensible des voies respiratoires et d'autres allergies provenant de l'inhibition de l'activation de cellules sanguines inflammatoires telles que les éosinocytes ; de maladies auto-immunes telles que l'atopie et le rhumatisme ; de la dépression associée au métabolisme perturbé du cerveau ; de l'infarctus cérébral ; de la démence sénile ; des troubles de la mémoire associés à la maladie de Parkinson ; du rhumatisme, de l'ostéoporose, des diabètes de type I et de type II, des cancers, des infections par le VIH, du SIDA, du choc provoqué par des toxines intracellulaires ; et des maladies inflammatoires et des maladies auto-immunes.